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General introduction and 
Outline of the thesis  
Introduction 
Aortic stenosis (AS) has become the most frequent type of valvular heart disease in Europe and 
North America. As it primarily presents as calcific AS in adults of advanced age (2–7% of the 
population >65 years), its prevalence is expected to increase further in the future with an aging 
population. 1,2 
Severe AS is associated with debilitating symptoms (shortness of breath, angina, dizziness, or 
syncope), and reduced survival if left untreated. In fact it imposes a pressure overload on the left 
heart causing left ventricular hypertrophy, in turns leading to systolic and diastolic dysfunction, 
recognized risk factors for cardiac morbidity and mortality. 
According to European Society of Cardiology guidelines, aortic valve replacement (AVR) is the 
definitive therapy for all patients with symptoms and severe AS, or severe AS with left ventricular 
systolic dysfunction. 3 
Traditionally, surgical AVR has been carried out with cardiopulmonary bypass, using either a 
mechanical or biological valve prosthesis. Valve sizing is performed intraoperatively using 
manufacturer specific sizing devices after excision of the native valve. However, approximately the 
30% of patients referred for AVR are denied surgery because of advanced age, left ventricular 
dysfunction or comorbidities. 4 Treatment of high surgical risk patients has been modified with the 
introduction of  transcatheter aortic valve implantation (TAVI) in 2002. 5-7 The procedure is performed 
off cardiopulmonary bypass via a percutaneous transarterial (usually transfemoral) approach or via a 
transapical approach by limited left thoracotomy. During the procedure a stent-mounted pericardial 
prosthesis is implanted within the native valve, displacing the native valve leaflets into the sinuses of 
Valsalva. Currently, both self-expanding and balloon expandable valve prostheses are commercially 
available and TAVI has been predominantly performed using either the balloon-expandable Edwards-
Sapien valve (Edwards Lifesciences, Irvine, CA, USA) or the self-expanding Medtronic CoreValve 
device (Medtronic, Inc., Minneapolis, MN, USA), both of which have received CE Mark. 8,9 
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The balloon-expandable Edwards-Sapien valve consists of three pericardial bovine leaflets 
mounted within a stainless steel tubular-slotted stent which has an outer diameter of 23 mm or 26 
mm depending on the size of the valve (23 or 26 mm inflow). The following iteration (Sapien XT), 
provided in four sizes (20-23-26-29 mm), has a cobalt-chromium lower profile frame with an 
enhanced semi-closed leaflet design. A fabric cuff with an unscalloped construction at the inflow 
provides an effective seal for 7–8 mm of the stent, which is the target for placement across the aortic 
annulus (AoA). The valve is specifically designed to fit into the AoA and usually positioned below the 
coronary ostium. The latest iteration, Edwards Sapien S3, incorporates a stent and leaflet design that 
allows for crimping to a reduced profile as compared with the previous devices. As with these earlier 
devices, the inflow of the S3 is covered by an internal polyethylene terephthalate skirt. However, the 
S3 incorporates an additional outer polyethylene terephthalate cuff to enhance paravalvular sealing. 
This sealing cuff has no filling and functions like a parachute by bulging outward. 10 
The CoreValve is made of porcine pericardial tissue sewn to form a trileaflet valve mounted 
within an asymmetrical trilevel self-expanding nitinol frame. The lower portion of the frame affixes 
the valve to the left ventricle outflow tract, the mid-portion has a constrained waist that must be 
deployed at the level of the sinuses of Valsalva and coronary ostia and the upper section is designed 
to fix and stabilize the prosthesis in the ascending aorta. The Corevalve is designed for arterial access, 
generally performed through the femoral or subclavian artery, but direct aortic access is also an 
alternative and there are case reports of deployment using a transapical route. 10 Figure 1 
 
Figure 1. Left. Edwards Sapien Valve (up), Edwards Sapien S3 (bottom). Right. Medtronic 
Corevalve. 
Clinical trials have shown TAVI to have outcomes similar to surgical AVR up to 2 years after the 
procedure and excellent outcomes have been confirmed by registry data, with overall survival of 76% 
at 1 year. 11-14 It is estimated that >100 000 TAVI have been performed between 2002 and 2014. It has 
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also become evident that clinical outcomes following TAVI are directly related to appropriate patient 
selection and valve choice.  
Pre-procedure imaging is vital to assess the severity of AS, identify eligible candidates, plan the 
interventional approach, and select the appropriate prosthesis according to the anatomical features. 
Imaging is pivotal during and after the procedure, guiding prosthesis deployment, providing 
information regarding valve position, identifying immediate complications, and assessing outcomes.  
Before TAVI, accurate measurement of the aortic root dimensions is essential for the selection 
of eligible candidates for the procedure and to ensure the appropriately sized valve prosthesis is 
chosen. Existing valves are designed for a specific range of annulus sizes and patients with annulus 
dimensions outside these ranges are not eligible for TAVI. Valve undersizing may lead to paravalvular 
regurgitation or device embolisation, while valve oversizing exposes the patient to the risk of aortic 
root rupture, significant conduction disturbance requiring pacemaker implantation or device 
underexpansion. Significant paravalvular aortic regurgitation (PAR) (greater than grade 2) is an 
independent predictor of late mortality in patients who undergo TAVI. 15 This parameter is the most 
commonly used outcome measure in TAVI sizing studies. 
Once it has been determined that the patient has severe AS and from a clinical perspective is a 
suitable candidate for TAVI, detailed assessment of the aortic root is required and, in particular, AoA 
sizing is crucial for accurate selection of prosthesis size. 
However, the AoA is not a true annulus in the sense of a fibrous ring surrounding the 
ventricular outflow tract and supporting the valve leaflets. There are several rings, at least 3 circular 
rings and 1 crown-like ring, to be found within the aortic root, not all corresponding to discrete 
anatomic structures. The annulus described by surgeons is usually the semilunar crown-like structure 
demarcated by the hinges of the leaflets. The valvar leaflets are attached throughout the length of 
the root. Seen in three dimensions, therefore, the leaflets take the form of a 3-pronged coronet, with 
the hinges from the supporting ventricular structures forming the crown-like ring. The top of the 
crown is a true ring, the sinutubular junction, demarcated by the sinus ridge and the related sites of 
attachment of the peripheral zones of apposition between the aortic valve leaflets. It forms the outlet 
of the aortic root into the ascending aorta. The semilunar hinges then cross another true ring, the 
anatomic ventriculoarterial junction. The base of the crown is a virtual ring, formed by joining the 
basal attachment points of the leaflets within the left ventricle. 16 Figure 2 
This virtual annulus is not circular but rather elliptical in a large proportion of patients. 17,18 The 
shape of the annulus must be assessed in all patients, as eccentricity of the annulus is associated with 
a higher incidence of significant post-procedural PAR. Valve dimensions and geometry change during 
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the cardiac cycle, with root dimensions becoming larger and adopting a more circular conformation 
during systole. 19-21  
 
Figure 2. Model of the coronet shaped aortic valve annulus (left) and of the long-axis view of 
the left ventricle with examples of measuerments relevant to TAVI (right). 
Further important aspects of imaging should be considered before TAVI. Particular 
considerations include leaflet morphology and extent and distribution of calcifications. Bicuspid 
valves have a more eccentric anatomy which may complicate valve positioning and lead to PAR. 22 The 
extent and distribution of calcification of the leaflets, sinuses, and the mitral valve annulus in the 
region of the mitral–aortic continuity must be assessed. Annular and commissural calcification and 
reduced annulus deformity is associated with a higher incidence of post-procedure PAR. 23 Extensive 
bulky calcification of the aortic valve leaflets may obstruct the coronary ostia, particularly in cases 
where the coronary ostia are low relative to the aortic annulus. 24 
In the majority of cases, the orifices of the coronary arteries arise within the 2 anterior sinuses 
of Valsalva, usually positioned just below the sinutubular junction. 16 It is not unusual, however, for 
the arteries to be positioned superior relative to the sinutubular junction. In a study of 51 normal 
postmortem hearts, the mean distance measured from the orifice of the left coronary artery to the 
basal attachment of the corresponding leaflet was 12.6±2.61 mm, and for the right coronary artery it 
was 13.2±2.64 mm. 25 Knowledge of the location of the coronary arteries, of course, is essential for 
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appropriate percutaneous replacement of the aortic valve. The valvar prostheses are designed such 
that a skirt of fabric or tissue is sewn within the stent or frame to help to create a seal and prevent 
paravalvar leakage. In situations in which the coronary arteries take their origin low within the sinus 
of Valsalva and/or the prosthesis is placed too high, the skirt may obstruct their orifices and thus 
impede coronary arterial flow. Furthermore, when the valve is deployed, it crushes the leaflets of the 
native valve against the aortic wall. The combination of a relatively low-lying coronary artery ostium 
and a large native aortic valvar leaflet therefore can obstruct the flow into the coronary arteries 
during valvar deployment. Thus, measurement of the height of the takeoff of the coronary arteries is 
important before valvar implantation. Figure 2 
Several studies comparing different imaging modalities have been performed to assess TAVI 
sizing strategy. Traditionally sizing has been based upon a direct measurement of AoA diameter in the 
long axis plane by two-dimensional (2D) imaging techniques (transthoracic echocardiography (TTE), 
transesophageal echocardiography (TEE) or aortic contrast angiography). This method has limitations; 
these include the fact that they only measure the AoA in a single plane, with uncertainty as to 
whether the measurement plane is passing through the central point of the AoA. In addition, 2D 
methods assume circular annulus geometry despite a mounting body of evidence that this is not the 
case. Compared to 2D echocardiography, traditionally the gold standard, AoA measurements made 
by 3D imaging techniques (3D TEE, MDCT, MRI) may be more accurate. While there is strong 
correlation between these methods, there is a signiﬁcant negative bias for 2D echo measurements as 
the measurements are traditionally made in the aortic long axis views, which do not correspond to 
the maximum dimension of the virtual basal ring; in fact, measurements made using the basal 
attachment of the leaﬂets do not transect the full diameter of the outﬂow tract but instead a tangent 
cut across the root. 17-19 
Moreover, coronary ostia impairment due to the presence of low coronary ostia and/or the 
occluding effect of aortic leaflets displacement by prosthetic percutaneous implantation is included 
between the possible life-threatening complications of the procedure. 24 The position of the coronary 
arteries relative to the AoA is evaluated traditionally using invasive angiography which is often 
performed in most of the patients preoperatively in order to study coronary arteries and peripheral 
vessels. However, the angiographic procedure shows the bias due to its 2D nature and in some cases 
it may carry an high risk of complications. Therefore MDCT has been reported as a valid alternative to 
angiography. However, it has also been demonstrated that the distance between the AoA and the left 
main ostium can be measured by 3D TEE. 26 
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3D imaging techniques have also proved superior for the prediction of PAR in studies where 
valve sizing was based upon 2D echo. PAR is one of the most important predictors of morbidity and 
mortality after TAVI and, as such, is a commonly used outcome measure in clinical trials involving 
TAVI. The incidence and degree of PAR depend critically on the valve sizing. In fact, valve undersizing 
related to 2D-based AoA measurements may lead to significant PAR or valve embolization. 27-33 On 
the other hand, prosthesis oversizing has been associated with aortic root rupture and post-
procedural conduction disturbance. 34,35 
Objective and outline of the thesis 
The objective of this thesis is to investigate the incremental value of a multimodality imaging 
approach to the evaluation of the anatomy of the aortic valve apparatus in TAVI patients. 
In Chapter 1 to 3 feasibility and accuracy of 3D imaging modalities in the assessment of aortic 
valve apparatus in TAVI patients will be introduced. In particular, the 3D TTE and MRI feasibility and 
accuracy in the measurement of AoA will be explored. Thereafter, feasibility and accuracy of 3D TEE 
versus CT for the evaluation of AoA to left main ostium (LM) distance will be investigated. 
Chapter 4 and 5 will discuss the additional prognostic value of 3D techniques (TEE and MDCT) 
in the prediction of PAR in TAVI patients. 
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Chapter 1 
Feasibility and accuracy of three-dimensional transthoracic echocardiography vs. 
multidetector computed tomography in the evaluation of aortic valve annulus in patient 
candidates to transcatheter aortic valve implantation. 
Tamborini G, Fusini L, Muratori M, Cefalù C, Gripari P, Ali SG, Pontone G, Andreini D, 
Bartorelli AL, Alamanni F, Fiorentini C, Pepi M. Eur Heart J Cardiovasc Imaging. 2014 
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Abstract  
Aims. Proper measurement of the aortic annulus (AoA) is crucial for the success of 
transcatheter aortic valve implantation (TAVI). Transthoracic echocardiography (TTE) is the first step 
to assess AoA diameter, but a two-dimensional TTE (2DTTE) measurement is no longer accepted as 
the sole determinant of prosthetic size. The aims of the study were to evaluate feasibility and 
accuracy of three-dimensional TTE (3DTTE) estimation of AoA dimensions in comparison with 
multidetector computer tomography (MDCT). 
Methods and results. We enrolled 100 consecutive patients referred for TAVI. Feasibility of 
AoA evaluation was 91% for 3DTTE and in 90% for MDCT. In 81 of 100 patients, AoA maximum 
diameter (max-D), minimum diameter (min-D), and area were measured and compared using 2DTTE, 
3DTTE, and MDCT. Image quality of 3DTTE was sufficient in 47, good in 46 and optimal in 7%. High 
correlations (P , 0.001) were found between MDCT and 3DTTE (max-D: r ¼ 0.89; min-D r ¼ 0.86; area: 
r ¼ 0.93), and between MDCT and 2DTTE (min-D: r ¼ 0.81; area 0.78). The 3DTTE measurements 
were found to be highly reproducible on intra- and interobserver variability analyses. Regarding the 
choice of prosthesis size, agreement between 3DTTE and MDCT was very good (k ¼ 0.84, P , 0.001) 
while it was poor between 2DTTE and MDCT (k ¼ 0.36, P , 0.001). 
Conclusions. 3DTTE may be a valid imaging alternative in patients unsuitable for MDCT during 
the preoperative evaluation for TAVI. Evaluation of AoA through 3DTTE is feasible, and 
measurements closely approximate those of MDCT thus improving TTE accuracy in identifying the 
correct prosthesis size. 
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Introduction 
Transcatheter aortic valve implantation (TAVI) has become a valid alternative to conventional 
surgery in selected high-risk patients. 1-4 However, a post-procedural paravalvular aortic regurgitation 
(PAR), has been frequently described. In the majority of patients PAR after TAVI is mild grade, while 
the incidence of moderate or severe PAR is low. 5-7 Although a mild PAR is known to be not associated 
with a dismal impact on left ventricular (LV) function and patient survival over the first year, recent 
reports have suggested that even a mild PAR could negatively impact mid- and long-term prognosis. 8-
9 Valve sizing has been shown to be one of the strongest predictors of PAR, then an accurate pre-
procedural evaluation of patients candidates for TAVI is mandatory to select the prosthesis size. 10-13 
Measurement of aortic annulus (AoA) dimension before TAVI has been traditionally and most 
commonly performed using transthoracic (TTE) and/or multidetector computed tomography (MDCT), 
while transesophageal echocardiographic (TEE) imaging (2D and 3D) is usually restrict to the intra-
operative evaluation14-23 and magnetic resonance imaging (MRI) is not  a standard perioperative 
procedure even though is an accurate method. 24 However, up to 20% of patients undergoing TAVI 
cannot undergo to MDCT due to various contraindications. The accuracy of 2DTTE in defining AoA 
dimensions is lower in comparison to MDCT and 3DTEE. 25 Recently 3DTTE has been demonstrate to 
overcome 2D echo imaging limitations in different clinical settings. 26,27 The aim of this study was 
twofold: to assess feasibility and accuracy of 3DTTE compared to 2DTTE and MDCT for the 
measurement of AoA dimensions in the preoperatory evaluation of patients candidates to TAVI; to 
evaluate whether the 3 imaging methods impact differently on the choice of the prosthesis size. 
Methods 
Study population 
From February 2013 to February 2014, 100 consecutive patients with severe symptomatic 
aortic stenosis were referred to our Institute for TAVI. Inclusion criteria were the presence of severe 
aortic valve stenosis (mean trans-aortic pressure gradient >40 mmHg or an aortic valve area <1cm2) in 
cases with very high or prohibitive risk for surgical aortic valve replacement and a predicted post-
implantation survival greater than 12 months. Exclusion criteria was the presence of a bicuspid aortic 
valve. 
20 
After a complete pre-procedural imaging (2DTTE, 3DTTE, MDCT and, when necessary, 
angiography to assess coronary, and aorto-ilio-femoral system) and clinical evaluation (assessment of 
operative risk, comorbidities, previous thoracic surgery or radiation and physical frailty) 27, 28 all the 
patients were evaluated by a multidisciplinary heart team including cardiologist, cardiac surgeon, 
interventional cardiologist, imaging specialist and cardiac anesthesiologist 19 to be finally admitted to 
the procedure.  
In all patients, 2DTTE, 3DTTE and MDCT were performed within 48 hours each other and TTE 
preceded MDCT. The operators (echocardiographers and radiologists) were blinded to measurement 
of the other 2 modalities. TEE was perfomed only in cases undergoing TAVI. 
Transthoracic echocardiography  
TTE was obtained with patients in the left lateral decubitus position using a commercially 
available system (iE33 system, Philips Medical System, Andover, Massachusetts with a S5-1 sector 
array probe). Real-time 3DTTE was performed immediately after the 2D examination, with the same 
ultrasound unit, using an X3-1 matrix array probe. For each patient measurement of AoA diameter 
with 2DTTE (2DTTE min-D) was performed in systole in a parasternal long-axis view on the left 
ventricular outflow tract at the points of insertion of the right and non-coronary aortic leaflets (Figure 
1). The 2DTTE AoA area was than calculated using the formula: AoA=(2DTTE min-D/2)2π, with the 
assumption that the AoA had a circular configuration. 
Moreover, real-time zoomed 3D or full volume images containing the whole aortic apparatus 
were acquired for quantitative analysis. Measurements on 3D data sets were obtained off-line with a 
commercially available software package (3DQ, Q-Lab version 7.0, Philips Medical Systems). 
The 3D dataset was analyzed moving 3 different orthogonal cut planes similarly to the 
published TEE recommendation method. 22 The final cut plane was transversal, oriented to visualize a 
short-axis view of the AoA, and on this plane the maximum diameter (max-D), the minimum diameter 
(min-D) were measured and AoA area were traced in systole. Figure 1 
The quality of 3DTTE AoA reconstruction was graded as: (0) inadequate (these patients were 
not analyzed and excluded from the study), (1) sufficient (sufficient quality with rare artifacts), (2) 
good (good images without artifacts), (3) optimal (optimal images without artifacts). 
Transesophageal echocardiography 
Patients were imaged during TAVI procedure using a commercially available echocardiographic 
system (iE33, Philips Medical System, Andover, MA) equipped with a X7-2t probe, allowing 2D 
multiplane, real-time 3D and full volume TEE acquisitions. Accordingly to the current clinical practice, 
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a 2D acquisition in zoom mode of the left ventricular outflow tract from the mid-esophageal position 
with scanning planes from 115° to 160° was performed in order to assess precise measurements of 
AoA. Moreover, real-time zoomed 3D or full volume images containing the whole aortic apparatus 
were acquired. The 3D dataset was analyzed with the same modality used for 3DTTE for AoA 
evaluation and previously described. 
 
Figure 1. AoA measured by 2DTTE, 3DTTE and MDCT. Example of 3D TTE from the parasternal 
long axis view (A) and of AoA measurement. B. The 3D dataset was analyzed through 3 
different orthogonal cut planes: red plane (1) is a short-axis view of aortic root crossing AoA; 
green (2) and blue (3) planes are sagittal views of the ascending aorta. The red plane was 
shifted from aortic root towards left ventricular outflow tract until aortic valve cusps 
disappeared, allowing the measurement of the AoA. (4) The position and the relationship of 
each plane in the 3D dataset are shown. C. AoA diameter measured by 2DTTE in a parasternal 
long axis view. AoA minimum diameter, maximum diameter and area measured in a cross-
sectional plane of a 3DTTE (D) and multidetector computed tomography (MDCT, E) dataset. RV 
= right ventricle, LA = left atrium. 
Multidetector computed tomography  
All examinations were performed with a Discovery HD750 scanner (GE Healthcare, Milwaukee, 
Wisconsin). Scanning parameters were: slice configuration, 64 x 0.625mm; gantry rotation time, 
350ms; tube voltage, 120 kVp; and effective tube current, 650mA. Contrast enhancement was 
achieved with a triphasic injection of an 80-mL bolus of Iomeron 400mg/mL (Bracco Imaging S.p.A., 
Milan, Italy) through an antecubital vein at a 5-mL/s infusion rate, followed by 50 ml of saline 
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solution, and a further 50-mL bolus of contrast at 3.5mL/s. After the threshold level of 200 Hounsfield 
units (HU) in the right ventricle was achieved, patients were instructed to hold a deep breath, and the 
scan was started when a threshold of 200 HU was reached in the left atrium, allowing the 
synchronization of the arrival of the contrast media and the scan. Data acquisition was performed 
with retrospective electrocardiogram triggering. Image analysis was performed on a separate 
computer workstation. AoA was defined as a virtual ring formed by joining the basal attachments of 
the aortic leaflets. 13 max-D, min-D, and the area of AoA were measured in an orthogonal plane on 
the center line of the aorta in systole. 
Prosthetic valve sizing 
To evaluate the difference on TAVI strategy we indicated the theoretical prosthesis size based 
on 2D and 3D AoA measurements compared to MDCT values as gold standard. The SAPIEN XT valve 
(Edwards Lifesciences Inc, Irvine, California) in 3 different sizes (23-, 26-, and 29-mm expanded 
diameter) was considered. Currently there is no consensus regarding the gold standard imaging 
technique for AoA sizing. From a practical perspective the choice of the prosthesis size was made 
according to guidelines, 18-20 in particular the size was primary chosen depending of AoA diameters 
and, secondary, in the uncertain cases, on the base of AoA area. Our current practice  was to use both 
MDCT and echocardiographic data for sizing and the interventionist/surgeon in the event of 
discrepancy decided on the basis a) of her/his experience related to the specific prosthetic model, b) 
of the method that provided the best image and c) of other technical details (vascular accesses, 
coronary-aortic annulus distance, angiography). 
Statistical analysis 
Data are presented as mean and standard deviation for continuous variables, while categorical 
variables are presented with frequencies and relevant percentages. Normality of distributions for 
continuous variables was tested using the Kolmogorov-Smirnov test. Linear regression analysis with 
Pearson correlation coefficient was used to evaluate the relationship between 3DTTE and MDCT AoA 
measurements. Bland-Altman analysis was used to assess the inter-technique agreement by 
calculating the bias (mean difference) and the 95% limits of agreement (defined as 1.96SD around the 
mean difference). To assess the reproducibility of the 3DTTE measurements, intraobserver and 
interobserver variability were evaluated in a subset of 25 randomly selected patients. Each parameter 
was reevaluated ≥2 weeks later on the same 3DTTE dataset by the main investigator and by a second 
investigator who was blinded to the results obtained by the main investigator. Both intraobserver and 
interobserver variability are reported in terms of intraclass correlation coefficients (ICCs) and 
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coefficients of variation (CV, percentages). Moreover, Bland-Altman analysis was applied to evaluate 
the limits of intraobserver and interobserver agreement. The Cohen K statistic was used to assess 
agreement between 2DTTE, 3DTTE and MDCT prosthesis size indication. All statistical analyses were 
carried out with SPSS 20.0 (SPSS Inc., Chicago, IL). 
Results 
Clinical and echocardiographic characteristics of the study population are summarized in Table 
1. Of the 100 consecutive patients enrolled, 19 were excluded from the study for inadequate 
echocardiographic window (9 patients) or inability to obtain MDCT data for renal impairment or 
tomographic poor image quality due to atrial fibrillation, arrhythmias or tachycardia (10 patients). 
Therefore feasibility of AoA measurements was 90% for MDCT and 91% for 3DTTE and finally 81 
patients constituted our study population.  
Table 1: Clinical and echocardiographic characteristics of the study population (n=81). 
Variable  
Male (%) 38 (47%) 
Age (years) 81±7 
Body surface area (m
2
) 1.75±0.20 
Logistic EuroSCORE (%) 20.8±12.1 
Aortic valve area index (cm/m
2
) 0.69±0.13 
Aortic peak systolic gradient (mmHg) 81±24 
Aortic mean systolic gradient (mmHg) 49±16 
Left ventricular diastolic volume index (ml/m
2
) 56±22 
Left ventricular systolic volume index (ml/m
2
) 26±22 
Left ventricular ejection fraction (%) 59.9±11.9 
Left ventricular mass index (g/m
2
) 151±46 
Aortic regurgitation (1-4) 1.7±0.8 
Systolic Pulmonary pressure (mmHg) 41±12 
Values espressed as mean±SD or absolute count(%). 
The quality of 3DTTE AoA imaging was sufficient in 38 cases (46.9%), good in 37 cases (45.6 %) 
and optimal in 6 cases (7.5%).  
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Evaluation of aortic annulus dimensions  
Mean value of AoA measurements and correlation between each methods are shown in Table 
2. Significant correlations were found both between 3DTTE and MDCT and between 2DTTE and 
MDCT.  
Table 2. Mean values of aortic annulus measurements. 
 3DTTE MDCT 2DTTE r1 p1 Value r2 p2 Value 
Min-D (mm) 21.5±2.3 21.4±2.4 21.5±2.2 0.86 <0.001 0.81 <0.001 
Max-D (mm) 25.5±3.0 26.5±3.1  0.89 <0.001   
Area (mm
2
) 443.2±97.0 442.5±94.8 367.3±76 0.93 <0.001 0.78 <0.001 
Values espressed as mean±SD or absolute count(%). 
A significant correlation was also found between 3DTTE and MDCT AoA max-D measurements. 
In the evaluation of AoA area an excellent correlation was demonstrated between 3DTTE and MDCT. 
Besides 2DTTE underestimation of AoA area in comparison with MDCT, a good correlation between 
the 2 methods was observed . Figure 2 shows correlations between 3DTTE and MDCT AoA 
measurements together with the results of Bland Altman analysis . The quality of 3DTTE imaging did 
not affect these correlations. 
3DTEE was performed in 43 out of 52 patients who underwent TAVI (9 cases were excluded for 
contraindications to TEE or because the procedure was performed without TEE monitoring). A 
significant correlation was found between 3DTEE and MDCT AoA measurements (3DTEE max-D 
25.3±2.7mm, r=0,78, p<0.001; min-D 21.5±2.3mm, r=0.86, p<0.001; area 440.1±98mm2, r= 0.91; p< 
0.001) and between 3DTEE and 3DTTE (max-D: r=0.82, p<0.001; min-D: r= 0.83, p<0.01; area: r= 0.90, 
p<0.001). 
Intra- and inter-observer variability 
The 3DTTE measurements was found to be highly reproducible in terms of intra-observer 
variability both using ICCs (min-D, 0.83; max-D, 0.81; Area, 0.91) and CV (min-D, 2.8%; max-D, 3.2%; 
Area, 3.3%). Similar results were obtained for the inter-observer variability analysis (ICCs: min-D, 0.85; 
max-D, 0.81; Area, 0.91; CV: min-D, 3.3%; max-D, 3.0%; Area, 3.8%). The results of Bland-Altman 
analysis of the agreement between repeated measurements of min-D, max-D and area are depicted 
in Figure 3. 
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Figure 2. 3DTTE and MDCT Correlations and Agreements. Results of linear regression (top 
panels) and Bland-Altman analysis (bottom panels) for, from left to right, minimum aortic 
annulus (AoA) diameter (min-D), maximum AoA diameter (max-D), and AoA Area measured by 
3DTTE and MDCT. The dashed lines represent bias and the solid lines±1.96 standard deviation. 
LOA, limits of agreement. 
 
Figure 3. Inter-observer and Intra-observer Variability. Results of Bland-Altman analysis of the 
agreement between repeated measurements of minimum aortic annulus (AoA) diameter (min-
D), maximum diameter (max-D), and Area for inter-observer (top) and intra-observer (bottom) 
variability applied to 3DTTE images obtained in a subset of 25 randomly selected patients. The 
dashed lines represent bias and the solid lines±1.96 standard deviation. LOA, limits of 
agreement. 
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Theoretical impact of the 3 methods on the choice of prosthetic size 
Results of the theoretical impact of the measurements of aortic annulus dimensions using 
2TTE, 3DTTE and MSCT on the decision to perform TAVI procedure and to the selection of prosthesis 
size are shown in Figure 4. Agreement between 3DTTE and MDCT was higher (k=0.82) in comparison 
with agreement between 2DTTE and MDCT (k=0.34). The 3 cases with a too small AoA and the 2 cases 
with too larger AoA were correctly identified by 3DTTE vs MDCT. On the contrary 2DTTE was 
inaccurate in the evaluation of 1 too large and 1 too small cases. As concern prosthetic sizing 3DTTE 
was in agreement with MDCT in 89% and showed undersizing or oversizing in 3% and 6% patients, 
respectively.  
On the contrary, 2DTTE agreed in MDCT prosthesis sizing in 47/81 cases (58%), while an 
undersizing was observed in 30 (37%) and oversizing in 4 (5%) patients. 
Choice of prosthetic size and clinical outcomes in patients undergoing TAVI 
Of the 81 patients included in the study 52 underwent to TAVI. For clinical or anatomical 
contraindications TAVI procedure was denied in 29 cases: in 13 a surgical prosthesis was implanted, in 
3 a percutaneous balloon valvuloplasty was performed and in 13 medical therapy was maintained.  
In 45 out of 52 cases the implanted prosthesis size was concordant with MDCT and 3DTEE data. 
In one case the interventionist/surgeon based the decision on measurements suggested by MDCT 
(29mm) while 3DTTE indicated a lower size (26mm). In 5 cases the implanted prosthesis was 
oversized in comparison to MDCT data, while in one case was undersized (a 23-mm prosthesis was 
implanted despite both MDCT and 3DTTE suggested a 26-mm model). Successful TAVI was reached in 
all patients. No in-hospital death was observed. 
After the procedure  PAR was absent or trivial in 26 cases (50%), mild in 15 (29%), 
mild/moderate in 11 (21.2%). No patient had moderate/severe regurgitation. The incidence and 
degree of severity of PAR were not different in cases in whom the interventionist/surgeon decided in 
accordance or discordance with 3DTTE or MDCT data, but this analysis was limited by the small 
sample size. 
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Figure 4. Relationship between prosthesis size indication based on 3DTTE, MDCT, and 2DTTE 
measurements. MDCT was used as gold standard. The areas filled with a diagonal line pattern 
represent the number of patients with a different choice of the prosthesis size compared to 
MDCT. Dotted arrows indicate the actual MDCT size for those patients with a discordant size by 
2DTTE and 3DTTE measurements. The absolute number and relative percentages of concordant 
size, undersizing and oversizing of 3DTTE and 2DTTE vs MDCT was reported in the table. 
Discussion 
Accumulating data have reported promising results concerning procedural success, quality-of-
life improvement, and short-, mid-, and more recently long-term outcomes after TAVI in high-risk 
patients with severe aortic stenosis. 1-5 However, aortic regurgitation, mainly paravalvular, has been 
described in a relatively large number of patients after TAVI. The presence of significant, or even mild, 
PAR is an independent risk factor for mortality at short- and mid-term follow-up. 6-9 Incorrect valve 
sizing (together with commissural calcifications) has been proven to be the principal cause for 
postoperative PAR as well as it is known to be the principal guilty for severe complications such as 
annular ruptures. 10-13 Thus, an accurate anatomical evaluation and correct sizing of the AoA are 
mandatory for patient selection and prosthetic size choice. 
Even though there are large series of cases with different imaging modalities, there is no 
consensus regarding the ideal imaging method for AoA sizing and preoperatively a multimodal 
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assessment is suggested. Besides in guidelines 18-20 TTE, TEE and MDCT are all imaging modalities 
recommended as work-up study before TAVI, TEE in a conscious, or mildly sedated, patient may be 
frequently poorly tolerate in more critically cases and should be performed very carefully. For this 
reason in the preoperative phase 2DTTE and MDCT are routinely used, while TEE with fluoroscopy 
and angiography are generally reserved to the perioperative phase in the procedural setting. 
Moreover, AoA is not a circular ring but is a complex structure with an oval cross sectional 
shape. A 2D evaluation of AoA dimensions through 2DTTE or 2DTEE diameters fails to appreciate its 
elliptical geometry, whereas 3D imaging methods as MDCT or 3DTEE can overcome this limitation.25 
The accuracy of MDCT in identifying the correct prosthesis size has been well demonstrated 
and this is one of the most important reasons why MCDT may be considered the reference method, 
allowing a comprehensive evaluation not only of AoA morphology, but also of peripheral, carotid and 
coronary circulation.15,18,21 
The higher accuracy of 3DTEE in comparison to 2DTEE in the analysis of the AoA (using MDCT as 
gold standard) has been extensively proved. 18,29,30 A previous research of our group 17 showed that 
3DTEE was a valid modality for the measurement not only of AoA dimensions but also of left coronary 
cusp length and of the distances from left main coronary ostium to the AoA, in a large TAVI 
population. Recently in a “in vitro” model, MRI was also demonstrated to be the most accurate 
method for assessing the dimensions of the ring models. 31  In a clinical setting, Pontone 25 confirmed 
that aortic root assessment with MRI including AoA size, aortic leaflet length, and coronary artery 
ostia height is accurate compared with MDCT. 
To the best of our knowledge, data on 3DTTE in this field are lacking. Doddamani et al. 32 
compared 3DTTE and 2DTTE in the evaluation of LV out flow tract anatomy and dimensions in 53 
normal subjects and demonstrated that 3DTTE reconstruction of LV outflow tract is feasible and 
discussed the addition value of 3DTTE in aortic valve area estimation due to the use of LV outflow 
tract planimetric area in continuity equation. 
This is the first study aimed at the evaluation of 3DTTE analysis of AoA in patients with severe 
aortic stenosis undergoing a screening evaluation for TAVI. The main findings of our study are: a) 
3DTTE evaluation of AoA is feasible in the majority of the patients with low intra and inter observer 
variability; b) 3DTTE and MDCT measurements did not differ significantly, with excellent agreement in 
the selection of cases with too small or too large AoA (exclusion criteria for TAVI) and a good 
agreement in the choice of prosthetic size in cases scheduled for the procedure.  
In our study population feasibility of MDCT and 3DTTE were similar (89% vs 90% respectively) 
and 3DTTE images were good or optimal for AoA measurement in 43/81 cases. In the remaining 38 
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cases despite suboptimal resolution of 3DTTE , AoA planimetric area and diameters outline were 
possible in all of them.  
Even though it is well know that MDCT provides precise information about the AoA anatomy 
and it is considered the gold standard for the pre-operative assessment of TAVI candidates, not all the 
patients can be studied by MDCT for several reasons such as impaired renal function, severe 
breathlessness, and arrhythmias. MRI has been demonstrated to be a valid alternative in these cases, 
however in a recent series25 from the original population of 80 consecutive TAVI patients, 30 were 
excluded being unsuitable candidates for one or both the procedures (MDCT and MRI). 
Three-dimensional TTE does not require breath-old and contrast infusion, may be obtained at 
the bedside, in more critical cases, and also in the presence of arrhythmias. In fact, the area of 
interest is limited to the aortic apparatus and can be completely contained in a 3D live format 
avoiding multibeat full volume acquisition. The most important limit of the method is the dependency 
to the acoustic window of the patient. In our population an inadequate acoustic window was found in 
9 out of 90 cases. In the 10 out of 100 cases who could not undergo to MDCT (3 for renal impairment 
and 7 for arrhythmias), the preoperative AoA evaluation was obtained through 2D and 3DTTE and the 
correct prosthesis size was confirmed intra-operatively by 2D and 3DTEE.  
In the present study, no significant differences have been observed between 3DTTE and MDCT 
AoA measurements. On the contrary while no significant differences were present between all the 3 
methods in the evaluation of AoA min-D, the 2DTTE AoA area, geometrically derived from 2DTTE 
diameter, was considerably lower in comparison both with 3DTTE and MDCT planimetric surface 
area. These results may be expected due to the oval shape of AoA, with significant differences 
between maximum and minimum diameter that is generally observed in a antero-posterior position 
corresponding to the 2DTTE estimated diameter. Thus the geometrical derived 2D area (derived from 
AoA min-D) amplifies the difference between 2D and 3D modalities. Moreover, in a minority of cases 
of our series 3DTEE was also performed. As previously demonstrated14-18 our data confirm an 
excellent correlation between 3DTEE and MDCT AoA measurements. As expected in this subgroup we 
also found a very high correlation between 3DTTE and 3DTEE data, thus reinforcing the concept that 
3D modalities were superior in measurements of  AoA in comparison with the corresponding TTE and 
TEE 2D techniques. 
Clinical implications 
Accurate AoA measurements are critical for patient selection and successful valve implantation. 
While 2DTTE and 2DTEE have been the primary methods for AoA measurements, nowadays MDCT is 
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considered as the reference standard. The ability to manipulate imaging planes for AoA 
measurements is the main reason of MDCT accuracy. In this regard the potential of 3DTTE has been 
underappreciated. Our data demonstrate that 3DTTE (confirming 3DTEE data) 16-18,22,23 may easily 
allow AoA measurements. It may be proposed as a screening test not only for aortic valve stenosis 
diagnosis (inside a comprehensive 2D and Doppler examination) but also to identify too small or too 
large AoA and to indicate the presumable size of the different TAVI models. This is particularly useful 
in cases in whom MDCT or MRI are not suitable. Therefore, 3DTTE may be a gatekeeper to the 
procedure and in the different settings MDCT, MRI and 3DTEE may be utilized depending on the local 
strategies. Moreover the simplest method (2DTTE and 3DTTE) may be utilized in centers which do not 
perform TAVI and in which more advanced methodologies are not present to preselect candidates 
with severe aortic stenosis and high risk for surgery.  
All these data are in agreement with previous studies on 3DTEE vs. 2DTEE showing that 3DTEE 
provide more accurate information that 2DTEE with superior discrimination of post-TAVI 
regurgitation.7,12,33 
Study limitations 
This study is not a randomized one, however it includes a consecutive series of patients 
undergoing a multimodality imaging screening before TAVI. Only 52 out of 81 cases underwent the 
procedure. Therefore, imaging measurements allowed us to compare values of the different 
modalities in all cases evaluating the theoretical impact on the choice of prosthetic size and clinical 
outcomes and choice of the implanted prosthetic size in only 52 patients undergoing TAVI. 
3DTEE was performed in a subgroup of patients. Despite we could not perform a complete 
analysis and head-to-head comparison in all our cases (this was behind the scope of this study) 
measurements with 3DTEE showed an high correlation with both 3DTTE and MDCT values. 
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Chapter 2 
Comparison of accuracy of aortic root annulus assessment with cardiac magnetic 
resonance versus echocardiography and multidetector computed tomography in patients 
referred for transcatheter aortic valve implantation. 
Pontone G, Andreini D, Bartorelli AL, Bertella E, Mushtaq S, Gripari P, Loguercio M, 
Cortinovis S, Baggiano A, Conte E, Beltrama V, Annoni A, Formenti A, Tamborini G, Muratori 
M, Guaricci A, Alamanni F, Ballerini G, Pepi M.Am J Cardiol. 2013 
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Abstract 
The evaluation of the aortic root in patients referred for transcatheter aortic valve 
implantation is crucial.  
The aim of the present study was to compare the accuracy of cardiac magnetic resonance 
(CMR) evaluation of the aortic annulus (AoA) with transthoracic and transesophageal 
echocardiography and multidetector computed tomography (MDCT) in patients referred for 
transcatheter aortic valve implantation.  
In 50 patients, maximum diameter, minimum diameter and AoA, length of the left coronary, 
right coronary, and noncoronary aortic leaflets, degree (grades 1 to 4) of aortic leaflet calcification, 
and distance between AoA and coronary artery ostia were assessed.  
AoA maximum diameter, minimum diameter, and area by CMR were 26.4 – 2.8 mm, 20.6 – 2.3 
mm, 449.8 – 86.2 mm2, respectively. The length of left coronary, right coronary, and noncoronary 
leaflets by CMR were 13.9 – 2.2, 13.3 – 2.1, and 13.4 – 1.8 mm, respectively, whereas the score of 
aortic leaflet calcifications was 2.9 – 0.8. Finally, the distances between AoA and left main and right 
coronary artery ostia were 16.1 – 2.8 and 16.1 – 4.4 mm, respectively.  
Regarding AoA area, transthoracic and transesophageal echocardiography showed an 
underestimation (p <0.01), with a moderate agreement (r: 0.5 and 0.6, respectively, p <0.01) 
compared with CMR. No differences and excellent correlation were observed between CMR and 
MDCT for all parameters (r: 0.9, p <0.01), except for aortic leaflet calcifications that were 
underestimated by CMR. 
 In conclusion, aortic root assessment with CMR including AoA size, aortic leaflet length, and 
coronary artery ostia height is accurate compared with MDCT. CMR may be a valid imaging 
alternative in patients unsuitable for MDCT. 
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Introduction 
Accurate measurement of the aortic annulus (AoA) is essential for appropriate valve sizing in 
transcatheter aortic valve implantation (TAVI). Measurement of AoA before and during TAVI has been 
traditionally and most commonly performed using transthoracic (TTE) and transesophageal (TEE) 
echocardiography. However, multi-detector computed tomography (MDCT) has distinct advantages 
over 2D echocardiography such as exceptional spatial resolution and multiplanar reformatting 
capabilities and has demonstrated to be a feasible and accurate imaging modality for the evaluation 
of the aortic root morphology and dimensions that may influence or modify TAVI strategy in a 
considerable number of cases.1-5 Unfortunately, up to 20% of patients undergoing TAVI have clinical 
conditions that make them unsuitable candidates for MDCT 1. Moreover, MDCT requires contrast 
agent administration that may be a hazard issue in patients with reduced kidney function who are a 
substantial proportion of TAVI patients.6, 7 
Cardiac magnetic resonance (CMR) does not need administration of contrast agents, provides 
similar 3D multi-slice images of the aortic root and may be a valid alternative to MDCT. However, only 
few data are available regarding its accuracy in comparison with MDCT.8-10 Thus, the aim of this study 
was to assess feasibility and accuracy of CMR in comparison with MDCT for the evaluation of AoA, 
aortic leaflets length and AoA-coronary artery ostia distance in patients referred for TAVI.  
Methods 
Between January 2011 and June 2012, 80 consecutive patients with severe aortic stenosis were 
referred to our institute for TAVI. Exclusion criteria were severely impaired renal function (creatinine 
clearance <30 ml/min) (4 patients), inability to sustain a 10-s breath hold (2 patients), atrial fibrillation 
or other cardiac arrhythmias (9 patients), presence of pacemaker or intracardiac defibrillator (10 
patients) and claustrophobia (5 patients). According to the exclusion criteria, a total of 50 patients 
were included in the study (27 men, mean age 79.627.52 years, logistic Euroscore 22.48). Written 
informed consent was obtained from all patients and the study protocol was approved by the local 
ethical committee. 
 TTE was obtained with patients in the left lateral decubitus position using a commercially 
available system (IE33 system, Philips Medical System, Andover, MA) in the parasternal (long- and 
short-axis) and apical (2- and 4-chamber) views at baseline.   
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For each patient, end-diastolic and end-systolic left ventricle volumes were measured. Left 
ventricle ejection fraction was calculated by echocardiography biplane Simpson’s rule. The severity of 
aortic stenosis was assessed by the peak and mean aortic gradients, while the aortic valve area was 
calculated with the continuity equation. The aortic stenoses was graded according to the American 
College of Cardiology/American Heart Association guidelines.11 Regurgitation of the mitral and aortic 
valves was graded as none (grade 0), mild (grade 1), mild to moderate (grade 2), moderate (grade 3) 
or severe (grade 4) according to published guidelines. 11 
Measurement of AoA diameter by TTE was performed in systole in a parasternal long-axis view 
on the left ventricular outflow tract at the points of insertion of the right and non-coronary aortic 
leaflets (Figure 1). The AoA area by TTE was estimated using the following equation: (AoA-
diameter/2)2 * Π with the assumption that the AoA had a circular configuration.  
All patients underwent TEE (IE33 system, Philips Medical System, Andover, MA) with a 
multiplane probe in the mid-esophageal position at 110–135° for full visualization of the AoA. TEE 
measurements of AoA diameter and area (Figure 1) were obtained in the same way as described for 
TTE. TTE was repeated after TAVI before patient discharge and at 1 month.  
 
Figure1. Methodology for the assessment of the AoA using TTE and TEE. TTE (Panel A): the AoA 
diameter is measured in a parasternal long-axis view on the left ventricular outflow tract at the 
point of insertion of the right and non-coronary aortic leaflet in mid-systole (dotted line). TEE 
(Panel B): the AoA diameter is measured on the mid-esophageal 120° to 140° long-axis view on 
the left ventricular outflow tract at the point of insertion of the right and non-coronary aortic 
leaflet in mid-systole (dotted line). AoA: aortic annulus; TEE: transesophageal 
echocardiography; TTE: transthoracic echocardiography. 
The MDCT exams were performed with a Discovery HD750 scanner (GE Healthcare, Milwaukee, 
WI). All patients with a resting heart rate70 beats/min received oral dose of ivabradine (10 mg/die) 
for 24 to 48 hours before MDCT to achieve a target heart rate<70 bpm. No patients were excluded 
because target heart rate was not reached.  
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The MDCT parameters were slice configuration 64 x 0.625 mm, gantry rotation time 350 ms, 
tube voltage 120 KVp and effective tube current 650 mA. All patients received a double-injection 
protocol of an 80-ml bolus of contrast (Iomeron 400 mg/ml, Bracco, Milan, Italy) through an 
antecubital vein at an infusion rate of 5 ml/s, followed by 50 ml of saline. The scan was performed as 
follows: after contrast enhancement reached a predefined threshold of 200 HU in the right ventricle, 
patients were instructed to hold a deep breath and the scan was started when a predefined threshold 
of 200 HU was achieved in the left atrium using retrospective ECG triggering.  
AoA by MDCT was defined as a virtual ring formed by joining the basal attachments of the 
aortic leaflets.12 For each AoA, maximum diameter, minimum diameter  and area were measured in 
systole in an orthogonal plane on the center line of the aorta.1 (Figure 2). Aortic leaflet calcifications 
were assessed on a short-axis view and graded visually (grade 1: no calcifications, grade 2: mild 
calcifications, grade 3: moderate calcifications, grade 4: heavy calcifications) (13). Aortic leaflet length 
was defined as the distance from the basal attachment and the apex of the left coronary, right 
coronary  and non-coronary leaflets.1 (Figure 2).  
 
Figure 2. Methodology for assessing AoA size, aortic leaflet size and coronary artery ostia 
height using MDCT.  Measurements of AoA (Panel A-C): AoA is defined as a virtual ring formed 
by joining the basal attachments of aortic valve leaflets. For each AoA, maximum diameter, 
minimum diameter and area (white dot line) were measured in an orthogonal plane on the 
center line of the aorta obtained in oblique-coronal and oblique-sagittal views, respectively. 
Measurement of leaflet size (Panel D): the distance between the basal attachment and the 
apex of the leaflets (black dot line) is determined. Measurement of coronary ostia height (Panel 
E-G): a coronal view of the ascending aorta (E) and two short axis at the level of the left main 
coronary ostium (red line) and  AoA  (blue line) are obtained. The distance between these two 
lines corresponds to the coronary ostium height. AoA: aortic annulus; MDCT: multidetector 
computed tomography. 
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The coronary ostia height was defined as the distance between 2 orthogonal planes on the 
center line of the aorta centered at the level of AoA and the ostium of the left main coronary artery 
and right coronary artery .1 (Figure 2). For MDCT, the effective radiation dose was calculated as the 
dose-length product time a conversion coefficient for the chest (K= 0.017 mSv/mGy*cm).14 Each 
MDCT variable was measured by an expert reader blinded to the other imaging modalities.  
All patients were studied with a 1.5-T scanner (Discovery MR450, GE Healthcare, Milwaukee, 
WI) the same day of MDCT evaluation. Transaxial and coronal half-fourier acquisition single-shot 
turbo spin echo multislice pilot images were acquired during held expiration. Steady-state free 
precession cine acquisitions were then acquired, also during held expiration, without contrast agent 
injection due to the high contrast resolution between blood pool and cardiac chambers using the 
following parameters: echo time  1.57 ms, 15 segments, repetition time  46 ms without view sharing, 
slice thickness  8 mm, field of view  350 mm x 263 mm, and pixel size  1.4 mm x 2.2 mm. To acquire 
cine planes, multiple short axis and two-, three- and four-chamber long axis of left ventricle were 
reached according to guidelines.15 Using long-axis plane of the left ventricle, two long-axis view of the 
aortic root and ascending aorta were obtained (Figure 3). 
 
Figure 3. Methodology for assessing AoA size , aortic leaflet size and coronary artery ostia using 
CMR. Measurements of AoA (A to C): AoA is defined as a virtual ring formed by joining the 
basal attachments of aortic valve leaflets. For each AoA, maximum diameter, minimum 
diameter and area (white dot line)  were measured in an orthogonal plane on the center line of 
the aorta obtained in oblique-coronal and oblique-sagittal views, respectively. Measurements 
of leaflet size (D): the distance between the basal attachment and the apex of the leaflets 
(black dot line) is determined. Measurement of coronary ostia height (E to G): a coronal view 
(E) and 2 short axis of the ascending aorta (F and G)at the level of the left main coronary ostium 
(red line) and  AoA (blue line) are obtained. The distance between these two lines corresponds 
to the coronary ostium height.  
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Thus, serial short-axis cines orthogonal to the LVOT (3-mm thickness with 1.5-mm overlapping) 
were imaged including the entire aortic root (Figure 3).  
AoA by CMR was defined as a virtual ring formed by joining the basal attachments of the aortic 
leaflets. For each AoA, maximum diameter, minimum diameter  and area were measured in systole in 
an orthogonal plane on the center line of the aorta (Figure 3). Aortic leaflet length and and coronary 
ostia height were measured as previously described for MDCT (Figure 3).  
Each CMR variable was measured twice by one of the investigators (GP), while another blinded 
reader (DA) measured the same CMR variables once again to test intra-observer and inter-observer 
variability. All CMR readers were blinded to the other imaging modalities.   
TAVI were performed in a hybrid operating room with general anesthesia, endotracheal 
intubation, and fast-track anesthesia protocol by a combined team of cardiologists, cardiac surgeons 
and anesthesiologists. The Sapien valve (Edwards Lifesciences Inc, Irvine, CA) in three different sizes 
(23-mm, 26-mm and 29-mm expanded diameter) was used in all patients. The final choice of 
prosthesis size and approaching modality were made according to guidelines.16  
Statistical analysis was performed with the SPSS version 17.0 software (SPSS Inc., Chicago, Il). 
Continuous variables were expressed as mean±SD, and discrete variables as absolute numbers and 
percentages. The intra-observer and inter-observer variability for the evaluation of CMR variables was 
defined by the coefficient of variation. Student t test was used to test differences of continuous 
variables between the baseline and post-TAVI parameters. The Spearman’s correlation and Bland-
Altman analysis were used for comparing CMR to MDCT values. P value <0.05 was considered 
statistically significant.  
Results 
Clinical characteristics of the 50 patients included in the study are summarized in Table 1. All 
patients had severe aortic stenosis with normal left ventricle volumes and low-normal ejection 
fraction (Table 1). The overall effective radiation dose of MDCT was 15.45.3 mSv. The aortic root 
measurements by all imaging modalities and the differences between CMR versus other imaging 
modalities are reported in table 2 and 3, respectively. Both TTE and TEE showed a underestimation of 
the AoA area in comparison with CMR (p<0.01). On the contrary no differences were observed 
between CMR and MDCT except for aortic valve calcifications that have been underestimated by CMR 
(p<0.05). The inter-observer and intra-observer variability of CMR measurements  is shown in Table 4.  
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Table 1. Clinical and echocardiographic characteristics of study population. Data are presented 
as mean±SD. 
Variable Baseline After implantation 
Clinical characteristics   
Number of patients, n 50 --- 
Gender (men/women), n 27/23 --- 
Age (yrs) 79.6±7.5 --- 
Body mass index (kg/m
2
) 25.9±5.6 --- 
BSA (m
2
) 1.8±0.2 --- 
Logistic EuroSCORE 22.4±8 --- 
TTE characteristics   
LV EDV /BSA (ml/m
2
) 58.4±25.1 51.6±21.7 
LV ESV /BSA (ml/m
2
) 26.3±19.3 23.3±15.1 
LV EF (%) 57.8±11.8 57.4±12.2 
Mitral regurgitation (0-4) 1.0±0.8 1.0±0.7 
Peak aortic gradient (mmHg) 78±18.5 19.3±6.9 
Mean aortic gradient (mmHg) 47.8±12.2 10.8±5.0 
Aortic valve area/BSA (cm
2
/m
2
) 0.4±0.1 1.4±0.4 
Aortic regurgitation (0-4) 1.2±0.9 0.5±0.9 
Pulmonary pressure (mmHg) 39.3±10.4 36.8±8.6 
CMR characteristics   
LV EDV/BSA (ml/m
2
) 85.7±29.3 --- 
LV ESV /BSA (ml/m
2
) 46.1±41.6 --- 
LV EF (%) 55.3±13.9 --- 
RV EDV /BSA (ml/m
2
) 65.5±15.9 --- 
RV ESV /BSA (ml/m
2
) 24.6±10.7 --- 
RV EF (%) 63±10.3 --- 
Mitral regurgitation (ml) 3.4±6.9 --- 
Aortic valve area/BSA (cm
2
/m
2
) 0.4±0.1 --- 
Aortic regurgitation (ml) 4.2±8.0 --- 
Values expressed as mean Values espressed as mean±SD. 
With regard to AoA maximum diameter, minimum diameter and area, TTE (Figure 4) and TEE 
(Figure 5) showed only a moderate agreement versus CMR as showed by Pearson’s correlation and  
Bland-Altman analysis, respectively. On the contrary, CMR showed an excellent agreement with 
MDCT regarding to AoA root geometry (Figure 6), heights of aortic cups (Figure 7) and distance 
between AoA and coronary artery ostia (Figure 8). 
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Table 2. Aortic root measurements. 
Variable CMR TTE TEE MDCT 
AoA maximum diameter (mm) 26.4±2.8   26.5±2.8 
AoA minimum diameter (mm) 20.6±2.3 21.9±2.4 22.6±2.6 20.2±2.2 
AoA area (mm
2
) 450±86 380±82 404±90 445±85 
Aortic valve calcification (1-4) 2.9±0.8   3.4±0.7 
Lenght of the left coronary leaflet (mm) 13.9±2.2   14±2.3 
Lenght of the right coronary leaflet (mm) 13.3±2.1   13.3±2.3 
Lenght of the non coronary leaflet (mm) 13.4±1.8   13.4±2.0 
AoA-to-left coronary ostium distance (mm) 16.1±2.8   16.2±3.1 
AoA-to-right coronary ostium distance (mm) 16.1±4.4   16.0±4.3 
Values expressed as mean Values espressed as mean±SD. 
Table 3. Differences of aortic root measurements betweeen cardiac magnetic resonance (CMR) 
and other imaging methods. 
Variable CMR vs TTE CMR vs TEE CMR vs MDCT 
AoA maximum diameter (mm) 5.1±2.8* 4.3±2.6† 0±0.8 
AoA minimum diameter (mm) -0.9±2.2* -1.6±2† 0.4±1 
AoA area (mm
2
) 70.2±82.1* 44.9±76.1† 4.9±21.2 
Aortic valve calcification (1-4)   -0.4±0.2
§
 
Lenght of the left coronary leaflet (mm)   -0.1±0.5 
Lenght of the right coronary leaflet (mm)   0±0.7 
Lenght of the non coronary leaflet (mm)   0.1±0.6 
AoA-to-left coronary ostium distance (mm)   -0.1±1.1 
AoA-to-right coronary ostium distance (mm)   0.1±1.1 
Data are presented as mean±SD; *: p <0.01 for CMR versus TTE; †: p <0.01 for CMR versus TEE; §: p <0.05 
for CMR versus MDCT 
Table 4. Intra- and inter-observer variability of cardiac magnetic resonance measurements.  
Variable Intraobserver CV (%) Interobserver CV (%) 
AoA maximum diameter  1.4 2.1 
AoA minimum diameter  1.2 2.0 
AoA area 1.4 2.0 
Aortic valve calcification  2.8 3.9 
Lenght of the left coronary leaflet  2.0 2.3 
Lenght of the right coronary leaflet  2.1 2.5 
Lenght of the non coronary leaflet  2.0 2.4 
AoA-to-left coronary ostium distance  2.5 3.1 
AoA-to-right coronary ostium distance  2.4 3.0 
Values shown are coefficients of variation (CV) expressed as percentages. 
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Figure 4. Pearson’s correlation (upper panels) and Bland-Altman analysis (lower panel) 
between CMR and TTE  assessment of AoA maximum diameter,  minimum diameter and  area. 
AoA: aortic annulus; CMR: cardiac magnetic resonance; TTE: transthoracic echocardiography. 
 
Figure 5. Pearson’s correlation (upper panels) and Bland-Altman analysis (lower panel) 
between CMR and TEE assessment of AoA maximum diameter,  minimum diameter and  area. 
AoA: aortic annulus; CMR: cardiac magnetic resonance; TEE: transesophageal 
echocardiography. 
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Figure 6. Pearson’s correlation (upper panels) and Bland-Altman analysis (lower panel) 
between CMR and MDCT assessment of AoA  maximum diameter,  minimum diameter and  
area. AoA: aortic annulus; CMR: cardiac magnetic resonance; MDCT: multidetector computed 
tomography. 
 
Figure 7. Pearson’s correlation (upper panels) and Bland-Altman analysis (lower panel) 
between CMR and MDCT assessment of left coronary, right coronary and non coronary aortic 
leaflets. CMR: cardiac magnetic resonance; MDCT: multidetector computed tomography. 
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Figure 8. Pearson’s correlation (upper panels) and Bland-Altman analysis (lower panel) 
between CMR and MDCT assessment of the distance between aortic annulus (AoA) and left 
main coronary artery and right coronary artery ostia.  
According to AoA area measured by MDCT (2), in 2 patients both TTE and TEE suggested to not 
perform TAVI for too small AoA size despite a 23-mm prosthesis was implanted based on MDCT 
measurements without complications.  In other 2 patients TAVI was not performed because MDCT 
showed a too large AoA while both TTE and TEE suggested a 29-mm valve.  In the remaining patients, 
TTE and TEE suggested a smaller, equal or larger prosthesis in 14 (28%), 31 (62%), 1 patients (2%) and 
in 8 (16%), 34 (68%), 4 patients (8%), respectively. CMR suggested a smaller, equal or larger 
prosthesis in 1 (2%), 44 (88%) and 2 patients (4%) and agree with MDCT to not perform TAVI for too 
large AoA size in 1 patient (2%). Finally, in 1 patients (2%) CMR suggested to not perform TAVI for too 
large AoA size despite a 29-mm prosthesis was implanted based on MDCT measurements without 
complications and in 1 patients (2%) TAVI was not performed because MDCT showed a too large AoA 
while CMR indicated a 29-mm valve. Therefore the agreement to perform the procedure and the 
agreement for prosthesis size between TTE, TEE and CMR vs MDCT were 92% and 62%, 92% and 68%, 
96% and 88%, respectively. 
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Discussion 
Accumulating data have reported promising results concerning procedural success, quality of 
life improvement, and short-, mid- and more recently long-term outcomes after TAVI in high-risk 
patients with severe aortic stenosis. Nevertheless, among clinically relevant complications of TAVI 
aortic regurgitation following valve implantation, which is mainly of paravalvular origin, has been 
shown to occur in a sizable proportion of patients and it is associated with a five-fold increase of one-
year mortality after the procedure. 17-19 Moreover, coronary artery occlusion has been reported to 
occur during TAVI. 20 Development of these serious complications depends on several factors that are 
in connection with aortic root anatomy and its relation to the implanted prosthesis. They include AoA 
shape and size, degree of annular and leaflet calcifications 21, left ventricle outflow tract anatomy, 
prosthesis/annulus incongruence 2,21,22, incorrect valve positioning 17, 18 and low take-off of coronary 
ostia with excessively enlarged valve leaflets. 17,18 Therefore, accurate evaluation of aortic root 
morphology and dimensions prior to TAVI integrating different non-invasive imaging modalities may 
reduce the chance for error and may prevent these complications.  
To the best of our knowledge, this is the first study showing that a comprehensive evaluation 
with CMR of aortic root including measurement of AoA size, aortic leaflet dimensions, and height of 
coronary artery ostia is feasible and accurate. Echocardiography has been commonly used for pre-
procedural assessment and has the advantage of providing physiologic data. However, there is 
growing evidence that 2D evaluation of the aortic root fails to appreciate its non-symmetric and 
complex geometry, while 3D imaging as can be performed with MDCT provides a more 
comprehensive and accurate morphologic and dimensional assessment. 1-5 Unfortunately, up to 20% 
of patients undergoing TAVI cannot be studied with MDCT.1 
Our study shows that 3D evaluation of the aortic root with CMR not only is feasible and 
accurate but may also circumvent some of the inherent limitations of MDCT. Indeed, compared to 
MDCT no contrast agent administration and radiation exposure is needed with CMR, while heart rate 
control is not a major issue due to a better temporal resolution of the latter technology that, unlike 
MDCT, does not loose image quality and accuracy with higher heart rate. 23 Tsang et al. 8 have 
demonstrated that CMR measurements of AoA are the most accurate in comparison with 3D-
echocardiography and MDCT in 28 explanted human hearts.  Burman et al. 9 studied 120 healthy 
volunteers with 1.5-T CMR. They utilized steady-state free precession cine acquisition aligned with 
the left ventricle outflow tract in oblique long-axis sagittal and coronal orientations, and defined AoA 
as the two diameters that transacted the aortic root at its widest point. Similarly, Jabbour et al. 10 
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studied 202 consecutive patients referred for TAVI with the same imaging technology demonstrating 
that CMR provides highly reproducible information for the assessment of these patients and for the 
prediction of post-procedure paravalvular aortic regurgitation. However, in both studies AoA was 
measured in a long-axis view as the distance between the basal attachments of the aortic cusps. This 
approach may underestimate true AoA size because it cuts a tangent across the root in a higher 
position as compared to the true basal ring. 12 Indeed, several studies demonstrated that a cross-
sectional measurement of the AoA is superior to conventional oblique coronal and sagittal planes 
sizing. 5 Our study indicates that CMR allows accurate short-axis visualization of the AoA and precise 
measurement of the virtual ring corresponding to the site of prosthesis deployment with high 
reproducibility and accuracy as compared to MDCT.  
Previous reports showed that assessment of coronary ostia height and aortic valve leaflet 
dimensions is a key step for patient selection and procedural planning in order to prevent coronary 
obstruction during TAVI. Although rare, this is a life-threatening complication that has been 
associated with a short distance between AoA and coronary ostia and excessively enlarged aortic 
valve leaflets (24). Our study shows that CMR can provide accurate estimation of both variables with 
good reproducibility, as demonstrated by a very low inter-observer and intra-observer variability.  
An intrinsic shortcoming of CMR is reduced visualization of calcium burden and this is 
confirmed in our study by the lower score of aortic leaflet calcifications observed with CMR as 
compared to MDCT. However, despite aortic valve calcification has been demonstrated to be a 
predictor of post-procedure paravalvular regurgitation, precise calcium estimation does not have a 
key role in patient selection and TAVI planning. 
An emerging issue in patients undergoing TAVI is acute kidney injury. Indeed, a recent meta-
analysis reports a 20.4% pooled estimate rate of renal insufficiency after TAVI and worsening of renal 
function has been demonstrated to be a strong predictor of mortality (25, 26). This complication is 
likely multifactorial.25,26 However, pre-procedural aortic root evaluation with CMR without i.v. 
gadolinium injection  has the advantage of reducing the total amount of contrast agent decreasing 
the risk of nephrotoxicity.  
Finally, in our study the overall radiation exposure of MDCT was 15.42 mSv, a value that is 
higher than the 10 mSv cut-off value suggested by the American Heart Association. Although the use 
of prospective ECG-triggering instead of retrospective ECG-triggering should allow a significant 
reduction of effective radiation exposure during MDCT 27, this is not applicable in patients with heart 
rate>65 bpm 27 due to the presence of misalignment artefacts. These patients are common in 
population with aortic stenoses such as in our study. Moreover, a scan covering the entire cardiac 
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cycle is mandatory due to the different measurements of AoA between systole and diastole. 28 This is 
only possible by using the retrospective ECG-triggering. However, although the high radiation 
exposure may be a minor hazard in an elderly population, future technology developments and 
increased clinical experience will likely allow to offer TAVI even to younger patients in whom an 
imaging modality without ionizing radiation such as CMR may be of significant value.  
A number of limitations of this study should be addressed. First, this is a single-center study 
that enrolled a relatively small number of patients. However, the strong correlation observed 
between CMR and MDCT suggests that the level of accuracy demonstrated by CMR could be 
replicated also in a larger patient population. Second, our measurements apply to the balloon-
expandable Sapien valve that was the only prosthesis used in this study. Third, CMR accuracy was not 
assessed against a true gold standard.  However, correlation between different imaging modalities is 
still an issue of debate and MDCT evaluation has demonstrated to predict important clinical end 
points such as post-procedure PAR. Fourth, also CMR could not be performed in a subgroup of 
patients.  
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Abstract 
Objectives. The aims of this study were to analyze in a large series of patients undergoing 
transcatheter aortic valve implantation (TAVI): 1) the accuracy of 3-dimensional transesophageal 
echocardiographic (3DTEE) measurement of left coronary cusp (LCC) length and of the distances 
from left main coronary ostium (LM) to the aortic annulus (AoA) pre-operatively and to the aortic 
prosthesis post-operatively; and 2) the role of the 3DTEE measurements in predicting the prosthetic 
deployment and the association between prosthesis position and aortic regurgitation (AR) and/or 
prosthesis-patient mismatch (PPM). 
Background. Coronary ostia occlusion is a possible complication in TAVI; therefore, the careful 
pre-operative evaluation of AoA-LM and LCC length, and the post-operative analysis of the 
relationship between the prosthesis and LM, may influence the procedural outcomes. Even though 
multidetector computed tomography (MDCT) is the gold standard pre-operatively, sometimes it 
cannot be performed 
and it is rarely repeated post-operatively. 
Methods. In 122 patients undergoing TAVI, pre-operative AoA-LM and LCC measurements 
obtained by 3DTEE and MDCT were compared. Post-operatively, the feasibility of 3DTEE evaluation 
of the prosthesis-LM distance was performed. The relationship between 3DTEE overlap of the 
prosthesis with the anterior mitral leaflet and AR/PPM was assessed. 
Results. Pre-operatively, 3DTEE AoA-LM (r = 0.83) and LCC (r = 0.69) significantly correlated 
with MDCT. Post-operatively, 3DTEE prosthesis-LM distance was 2.1±1.9 mm. The prosthesis reached 
or exceeded LM in 6 and 10 cases, respectively. Prosthesis overlap with mitral leaflet was 4.7±1.8 
mm. Significant correlation between the 3DTEE computed and nominal length of the prosthesis was 
found (r = 0.61). No correlations were found between prosthesis–mitral leaflet overlap and aortic 
regurgitation or PPM. 
Conclusions. AoA-LM distance and LCC length may be accurately estimated by 3DTEE, which 
may represent a valid alternative to MDCT. Pre- and post-3DTEE data concerning the aortic root, 
such as LM, aortic valve, and prosthetic morphology, give new insights into TAVI and its 
complications. 
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Introduction 
Transcatheter aortic valve replacement (TAVI) has become a valid alternative to conventional 
surgery in selected high-risk patients with severe and symptomatic aortic valve stenosis. 1,2 One of the 
major complications reported after TAVI is coronary ostia impairment 3-7 due to the presence of low 
coronary ostia and/or the occluding effect of aortic leaflets displacement by prosthetic percutaneous 
implantation. 
Therefore a careful preoperative evaluation of the distance between aortic annulus (AoA) and 
left main coronary ostium (LM) and of left coronary cusp (LCC) is necessary and an accurate analysis 
of the critical relationship between the prosthesis and LM postoperatively should be performed.  
Preoperatively AoA-LM distance and LCC length estimation are generally obtained through 
multidetector computed tomography (MDCT) which is the gold standard in this context, allowing an 
accurate assessment of aortic root geometry. 7-9 Unfortunately MDCT cannot be performed in 
arrhythmic patients or in cases with severe impaired renal function and it is rarely repeated 
postoperatively for clinical reasons. Moreover immediate post-procedural imaging inside the 
operatory theatre is possible only by using echocardiography or angiographic techniques.  
Three-dimensional transesophageal echocardiography (3DTEE) has been demonstrated very 
useful in the management of TAVI in preoperative evaluation of AoA dimensions 8,10 and may be used 
as substitute for MDCT in AoA measurement. The incremental value of its application in procedural 
monitoring of TAVI and of post-procedural result assessment is also well known. 11,12 Moreover few 
data are available concerning the immediate postoperative relationship between the device and 
coronary ostia. 
Our aims were to study in a large series of patients: 1) the feasibility of preoperative AoA-LM 
distance and LCC length measurements by 3DTEE; 2) its accuracy in comparison with MDCT-derived 
measurements; 3) the feasibility of postoperative 3DTEE evaluation of the distance between the 
prosthesis and LM; 4) the accuracy of the 3DTEE-derived measurements in predicting the stent 
landing zone as defined by the overlap of the prosthesis with mitral leaflet; and 5) the association 
between prosthesis deployment and regurgitation, positioning and spatial relation with LM. 
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Methods 
Study population 
From January 2008 to June 2011, 276 consecutive patients underwent TAVI using the Edwards 
Sapien prosthesis in Centro Cardiologico Monzino IRCCS.  
In all patients a transthoracic echocardiography was performed before surgery to confirm the 
severity of the aortic valve stenosis (mean trans-aortic pressure gradient ≥40 mmHg or an aortic valve 
area <1 cm2) 13 and to assess the feasibility of the percutaneous procedure (absence of aortic bicuspid 
valve, aortic annulus dimensions between >18mm and 26mm). 12,14 Before hospital discharge, after 
TAVI procedure, transthoracic echocardiography was repeated and the effective orifice area of the 
prosthesis was obtained using the continuity equation approach and indexed to body surface area. 
Prosthesis–patient mismatch (PPM) was defined in presence of orifice area ≤ 0.85 cm2/m2. 15-17 
Before TAVI procedure, an invasive coronary and peripheral vascular angiography was 
performed according to guidelines 14 in order to rule out coronary and peripheral disease. In 190 out 
of 276 patients, a MDCT exam was performed. In 268 patients, peri-procedural 2-dimensional TEE 
monitoring, completed with 3DTEE acquisitions, was performed. Exclusion criteria were: atrial 
fibrillation or other arrhythmias, impaired renal function, inability to sustain a 10 second breath-hold, 
presence of esophageal diseases or clinical contraindication to general anaesthesia during the 
procedure, stenosis of the left main and/or the proximal descending coronary artery. Therefore 122 
out of 276 patients were enrolled in this study.  
The study protocol was approved by the ethics committee and, prior to participation, informed 
consent was obtained from all patients. 
Transesophageal echocardiography 
Patients were imaged during TAVI procedure using a commercially available echocardiographic 
system (iE33, Philips Medical System, Andover, MA) equipped with a X7-2t probe, allowing 2D 
multiplane, real-time 3D and full volume TEE acquisitions. Image acquisition was performed by an 
experienced cardiologist. Preoperatively accordingly to the current clinical practice, a 2-dimensional 
TEE acquisition in zoom mode of the left ventricular outflow tract from the mid-esophageal position 
with scanning planes from 115° to 160° was performed in all patients in order to assess precise 
measurements of AoA and aortic root. Moreover, real-time zoomed 3D or full volume images 
containing the whole aortic apparatus and the proximal ascending aorta were acquired both pre- and 
post-TAVI for quantitative analysis performed with a commercially available software package (3DQ, 
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Q-Lab Version 7.0, Philips Medical Systems). Briefly, before TAVI the 3D dataset was analyzed moving 
3 different orthogonal cut planes: the first cut plane was transversal, oriented to visualize a short-axis 
view of the aortic annulus and on this plane the maximum diameter (Max-D), the minimum diameter 
(Min-D) and the area of AoA were measured. The second and the third were both longitudinal planes, 
one adjusted orthogonal to the short-axis in order to obtain a sagittal view of the ascending aorta. 
The other longitudinal plane was gradually rotated until the LM ostium appeared allowing the 
measurement of AoA-LM distance (Figure 1).  
 
 
Figure 1. AA-LM distance measured by 3DTEE. Example of 3-dimensional (3D) transesophageal 
(TEE) measurement of the distance between aortic annulus (AA) and left main coronary ostium 
(LM). The 3D dataset was analyzed through 3 different orthogonal cut planes: green plane (A) is 
a short axis view of aortic root crossing the LM; red (B) and blue (C) planes are sagittal views of 
the ascending aorta. The blue plane was gradually rotated until the LM appeared allowing the 
measurement of the distance between AA and LM ostium (white arrow). (D) The position and 
the relationship of each plane in the 3D dataset are shown. 
In addition, in the same plane, LCC length was assessed as the distance between the tip of the 
leaflet and the AoA (Figure 2). 
In the post-TAVI 3D dataset we evaluated: 1) L1 = the overlap of the prosthesis with the 
anterior mitral valve leaflet, defined as the distance between the ventricular edge of the aortic 
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prosthesis and the native AoA; 2) L2 = the distance between the distal edge of the prosthesis and LM 
ostium.  
 
Figure 2. LCC Length Measured by 3DTEE and MDCT. (Top) Example of 3DTEE measurement of 
the left coronary cusp (LCC) length. A short-axis view (A1) at the level of AA (top, left); a 
shortaxis view (A2) at the level of the tip of the leaflets (top, middle); a sagittal view of the 
ascending aorta with the LCC length (white line) measured as the distance between plane A1 
and A2 (top, right). (Bottom) Example of multidetector computed tomography (MDCT) 
measurement of the LCC length. A short-axis view (B1) at the level of AA (bottom, left); a short-
axis view (B2) at the level of the tip of the leaflets (bottom, middle); a sagittal view of the 
ascending aorta, with the LCC length (red line) measured as the distance between plane B1 and 
B2 (bottom, right). Abbreviations as in Figure 1. 
The 3DTEE prosthesis length was calculated as [(AoA-LM distance + L1) - L2] and this computed 
measurement was compared with the nominal prosthesis length (14mm, 17mm an 19mm for a 
23mm, 26mm and 29mm device, respectively) (Figure 3). 
A 3D dataset was considered unsuitable for analysis if it contained artifacts or if LM ostium was 
not clearly visible for artifacts or poor quality of the image. 
Finally after the device deployment and after removal of the catheters the presence of post-
procedural paravalvular aortic regurgitation (AR) was evaluated. Post-procedural AR was quantified 
according to standard echocardiographic color-Doppler method using the jet width and extension and 
graded as: 0 (absent), 1 (mild), 2 (mild to moderate), 3 (moderate to severe), 4 (severe). Paravalvular 
AR was considered significant if greater than or equal to 2. 
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Figure 3. Post-Operative 3DTEE Evaluation. Example of a 3DTEE post-operative evaluation of 
the aortic root and prosthesis. Three different orthogonal views are shown: (left) a short-axis 
view of aortic root at the level of the aortic prosthesis and the LM; (middle) a longitudinal view 
of the ascending aorta showing the aortic prosthesis length and the overlap of the prosthesis 
with the anterior mitral valve leaflet; and (right) a longitudinal view of the ascending aorta 
crossing the LM; this view allows the measurement of the distance between the upper edge of 
the prosthesis and the LM. Abbreviations as in Figure 1. 
Multidetector computed tomography 
All examinations were performed with a LightSpeed VCT XT Scanner (GE Healthcare, 
Milwaukee, Wisconsin). Scanning parameters were slice configuration 64 x 0.625mm, gantry rotation 
time 350 ms, tube voltage 120 kVp, and effective tube current 650 mA. Contrast enhancement was 
achieved with a tri-phasic injection of 80 mL bolus of Iomeron 400 mg/mL (Bracco, Milan, Italy) 
through an antecubital vein at a 5 mL/s infusion rate, followed by 50 mL of saline solution and a 
further 50 mL bolus of contrast at 3.5 mL/s. After the threshold level of 200 Hounsfield units (HU) in 
the right ventricle was achieved, patients were instructed to hold a deep breath, and the scan was 
started when a threshold of 200 HU was reached in the left atrium allowing the synchronization of 
the arrival of the contrast media and the scan. Data acquisition was performed with retrospective 
ECG-triggering.  
Image analysis was performed on a separate computer workstation. AoA was defined as a 
virtual ring formed by joining the basal attachments of the aortic leaflets. 18 Max-D, Min-D and the 
area of AoA were measured in an orthogonal plane on the center line of the aorta in systole. The 
distance between the AoA and the LM was defined as the distance between the short axis at the level 
of the LM and the short axis at the level of AoA (Figure 4).  LCC length was defined as the distance 
between 2 orthogonal planes on the center line of the aorta, centered at the basal attachment and 
apex of the LCC in end-diastolic phase (Figure 3). 
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Figure 4. AA-LM Distance Measured by MDCT Example of MDCT measurement of AA to LM 
distance. (A) A sagittal view of the ascending aorta; AA-LM was measured as the distance 
between the short axis at the level of the LM and the short axis at the level of the AA. (B) A 
short-axis view at the level of the LM. AN AO = aortic annulus; L Coro = left coronary artery; 
other abbreviations as in Figures 1 and 2. 
Statistical analysis 
Data are presented as mean and standard deviation for continuous variables, while frequencies 
and relevant percentages for categorical variables. Linear regression analysis with Pearson’s 
correlation coefficient was used to evaluate the relationship between computed and nominal 
prosthesis length, LCC length and AoA-LM distance, and between 3DTEE and MDCT measurements. 
Also, Bland-Altman analysis was used to assess the inter-technique agreement by calculating the bias 
(mean difference) and the 95% limits of agreement (defined as 1.96SD around the mean difference). 
A Chi-Square test was performed to investigate the association between prosthesis-mitral leaflet 
overlap, the entity of paravalvular AR and the presence of PPM. To determine the reproducibility of 
the AoA-LM distance, intra- and inter-observer variability were assessed in a subset of 30 patients as 
coefficient of variation, defined as the ratio between the standard deviation and the mean of the 2 
measurements, expressed as a percentage. During these repeated analyses, investigators were 
blinded to each other’s and prior measurements. A Bland-Altman analysis was performed to evaluate 
the concordance between the 2 observers and between the first observer and himself. All statistical 
analysis were performed using SPSS 17.0 (SPSS Inc., Chicago, IL). 
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Results 
All patients underwent to TAVI with a balloon-expandable Edwards SAPIEN valve (Edwards 
Lifesciences, Irvine, CA) through trans-apical (43 pts) or trans-femoral (79 pts) approach. The 
procedures were performed under general anesthesia with TEE and fluoroscopic guidance. A 23 mm, 
26 mm and 29 mm prosthesis were implanted in 58, 59 and 5 patients, respectively. Clinical baseline 
characteristics of the study population are reported in Table 1.  
Table 1. Baseline clinical and 2D echocardiographic characteristics of the study population.  
Clinical and echocardiographic parameter  
Age, yrs 81±7 
Male/female 39/80 
Body surface area (m
2
) 1.7±0.2 
Logistic EuroSCORE (%) 19±11 
NYHA functional class, %  
I 0 (0) 
II 38 (32) 
III 61 (51) 
IV 20 (17) 
Left ventricular ejection fraction, % 58±12 
Aortic valve area, cm
2
 0.65±0.16 
Aortic annulus, mm 21±2 
Left ventricular outflow tract, mm 20±2 
Sinus of Valsalva, mm 31±4 
Sinotubular junction, mm 27±4 
Mean transaortic pressure gradient, mmHg 52±15 
Values are mean±SD;, n/n, or n(%). EuroSCORE = European System for Cardiac Operative Risk Evaluation; 
NYHA = New York Heart association; 2D = 2-dimensional 
Paravalvular AR immediately post-TAVI was graded: 0 in 54 patients (44%), 1 in 52 patients 
(43%), 2 in 14 patients (11%), 3 in 1 patients (1%) and 4 in 1 patient (1%). Therefore, AR was greater 
than or equal to 2 in 16 patients (13%). The incidence of PPM post-TAVI was 45% (55 patients), as 
assessed by transthoracic echocardiography before hospital discharge. 
The measure of AoA-LM distance was feasible in 119 of 122 patients (97.5%) with a 3DTEE 
acquisition focused on the aortic apparatus and in all the patients with MDCT. Three-dimensional TEE 
estimation of the distance between LM and the prosthesis was feasible in 110 cases (90%).  
Table 2 shows mean values of the AoA-LM distance, LCC length, Min-D, Max-D and Area of AoA 
obtained by 3DTEE and MDCT for all patients and separately for each size of prosthesis implanted.  
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Table 2. Correlations between 3DTEE and MDCT measurements.  
All sizes 3DTEE MDTC r p value 
AoA-LM [mm] 13.5±2.2 13.9±2.2 0.83 <0.001 
LCC Length [mm] 13.7±1.8 13.6±1.8 0.69 <0.001 
Min-D [mm] 21.3±2.1 21.4±2.2 0.70 <0.001 
Max-D [mm] 24.6±2.3 25.3±2.2 0.68 <0.001 
Area [cm
2
] 4.1±0.7 4.3±0.8 0.76 <0.001 
Size 23 (n=57) 3DTEE MDTC r p value 
AoA-LM [mm] 12.9±1.6 13.5±1.9 0.77 <0.001 
LCC Length [mm] 13.1±1.8 12.9±1.7 0.60 <0.001 
Min-D [mm] 19.9±1.4 19.9±1.4 0.44 0.002 
Max-D [mm] 23.1±1.6 23.9±1.4 0.45 0.001 
Area [cm
2
] 3.6±0.4 3.7±0.4 0.51 <0.001 
Size 26 (n=57) 3DTEE MDTC r p value 
AoA-LM [mm] 13.9±2.2 14.1±2.3 0.82 <0.001 
LCC Length [mm] 14.2±1.6 14.1±1.7 0.73 <0.001 
Min-D [mm] 22.5±1.7 22.7±1.6 0.47 0.01 
Max-D [mm] 25.7±1.8 26.2±1.7 0.49 <0.001 
Area [cm
2
] 4.5±0.6 4.7±0.6 0.32 0.03 
Size 29 (n=5) 3D TEE MDTC r p value 
AoA-LM [mm] 16.2±3.2 16.2±3.5 0.99 <0.001 
LCC Length [mm] 15.4±1.3 14.5±1.9 0.58 0.31 
Min-D [mm] 24.0±1.1 25.1±1.3 0.82 0.09 
Max-D [mm] 28.3±2.2 30.0±0.9 -0.38 0.54 
Area [cm
2
] 5.4±0.6 5.9±0.4 0.37 0.54 
Values are mean±SD. AoA-LM= distance between aortic annulus and left main coronary ostium; Area  
aortic annulus area; LCC length= distance between the tip of the left leaflet and the aortic annulus; Max-
D and Min-D=maximum and minimum aortic annulus diameters; MDCT=multidetector computed 
tomography; 3DTEE= 3-dimensional transesophageal echocardiography. 
All measurements were significantly correlated as depicted in the scatterplots of Figure 5 
together with the results of Bland-Altman analysis showing a good agreement between the two 
techniques with a minimal underestimation of 3DTEE measurements compared with MDCT.  
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Figure 5. 3DTEE and MDCT correlations and agreements. Results of linear regression (left) and 
Bland-Altman analysis (right) for AoA-LM distance, LCC length, AoA area, minimum (min-D) and 
maximum (max-D) diameters, measured by 3DTEE and MDCT. Abbreviations as in Figure 1 and 
2. 
Three-dimensional TEE measurements of AoA-LM distance were found to be highly 
reproducible on both intra-observer and inter-observer variability analysis as depicted by lower 
coefficients of variation, 2.1% and 2.6% respectively. Figure 6 shows the results of Bland-Altman 
analysis of the agreement between repeated measurements of AoA-LM distance together with 
relevant bias and limits of agreement.  
The mean value of overlap with the anterior mitral valve leaflet (L1) was 4.5±1.9mm (range: -
2.0-9.5mm) and the distance between the distal edge of the prosthesis and the left main coronary 
artery ostium (L2) was 2.1±1.9mm (range: -2.0-6.5mm). The upper edge of the prosthesis reached (6 
cases) or overlapped (10 cases) LM ostium. 
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Figure 6. Interobserver and intraobserver variability. Results of Bland-Altman analysis of the 
agreement between repeated 3DTEE measurements of the distance between aortic annulus 
and left main (AA-LM) for interobserver (left) and intraobserver (right) variability obtained in a 
subset of 30 randomly selected patients.  
Table 3 shows 3DTEE derived anatomical data regarding AoA-LM distance (preoperatively) and 
the characteristic of the prosthesis implantation (postoperatively) in each of these 16 cases.  
Table 3. Pre- and post-operative 3DTEE measurements in each of the 16 cases in which the 
upper edge of the aortic prosthesis reached or overlapped LM ostium. 
N° 
3DTEE AoA-LM 
distance 
3DTEE PR-LM 
distance 
PR-anterior mitral 
leaflet overlap 
PR size 
Nominal PR 
length 
Computed PR 
length 
1 12.8 0 2.0 23 14 14.8 
2 12.3 0 3.0 23 14 15.3 
3 12.4 0 5.4 26 17 17.3 
4 11.7 0 3.0 23 14 14.7 
5 12.2 0 4.6 26 17 16.8 
6 11.4 0 6.0 26 17 17.4 
7 11.2 -1.0 3.7 23 14 14.8 
8 15.6 -1.0 3.0 29 19 19.8 
9 15.0 -1.0 2.0 23 14 15.4 
10 14.8 -1.5 1.0 23 14 16.5 
11 12.8 -1.6 1.8 23 14 15.9 
12 10.7 -1.6 4.0 26 17 16.4 
13 11.3 -2.0 4.0 26 17 17.0 
14 9.3 -2.0 3.0 23 14 14.3 
15 10.7 -2.0 1.5 23 14 15.6 
16 9.9 -2.0 4.0 26 17 17.6 
AoA=aortic annulus; LM=left main coronary ostium; PR=aortic prosthesis; 3DTEE=3-dimensional 
transesophageal echocariography 
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Figure 7 shows 3DTEE reconstruction of the distance between the upper edge of aortic 
prosthesis and LM in 2 different cases. 
 
Figure 7. Pre- and post-operative 3DTEE LM visualization. 3DTEE reconstruction of the aortic 
root and LM in 2 patients before (left panels) and after (right panels) TAVI. Solid arrow 
indicates the LM coronary ostium; dotted arrow indicates the upper edge of the prosthesis in 
the postoperative reconstruction. Top panels: pre- and post-operative reconstruction in a 
patient with the LM coronary ostium in a high position; the upper edge of the prosthesis is a 
few millimeter distant from the LM. Bottom panels: pre- and post-operative reconstruction in a 
patient with the LM in a low position; in the post-operative image the upper edge of the 
prosthesis is partially superimposed on the LM. 
There was a good correlation (r=0.64, p<0.001) between the 3DTEE computed and nominal 
length of the prosthesis (Figure 8). 
No differences in echocardiographic parameters were found in patients with suboptimal 
hemodynamic results (PPM or AR >2) and cases with optimal hemodynamic results. In particular no 
correlations were found between prosthesis-mitral leaflet overlap and paravalvular AR or PPM. 
Moreover no significant correlation was found between LCC length and AoA-LM distance.  
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Figure 8. Nominal vs 3DTEE prosthesis length. Correlation between prosthesis nominal length 
and prosthesis length as measured by 3D transesophageal echocardiography. Median values 
are depicted as squares; whiskers extend from the first quartile to the third quartile; outliers 
are shown as + symbols. 
Discussion 
Transcatheter aortic valve implantation is nowadays a valid alternative to surgical aortic valve 
replacement for the treatment of surgical high-risk patients with severe aortic valve stenosis. As in 
traditional surgical aortic valve replacement, after prosthesis implantation an immediate decrease of 
transvalvular pressure gradient and of systolic left ventricular pressure is expected. These changes are 
generally associated with a significant increase in coronary flow. 19,20 
However, coronary ostia impairment, due to the presence of low coronary ostia and/or to the 
occluding effect of the calcified native cusps crushed against the aortic wall after the prosthesis 
deployment, is included between the possible life-threatening complications of the procedure. 3-5 
Moreover, operator-related factors, such as high valve positioning or implantation of an oversized 
prosthesis, may also lead to postoperative complications.  
Several authors 8,10,21 demonstrated the importance of an accurate preoperative evaluation of 
the distance between AoA and coronary ostia in the selection of subjects candidates for TAVI, in order 
to avoid LM occlusion due to covering of coronary ostium by the upper part of the prosthesis or by 
left coronary cusp displacement. Therefore, even in the absence of defined guidelines, an AoA-LM 
distance lower than 10-11 mm is generally indicated as cut-off value under which a TAVI with 
Edwards Sapiens prosthesis may be contraindicated. 7,12,18 
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Since MDCT provides precise information of the aortic valve anatomy, it is considered the gold 
standard for the preoperative assessment of TAVI candidates. However, in these critical patients, 
impaired renal function, severe breathlessness, atrial fibrillation or other arrhythmias are frequently 
present and may contraindicate the employment of MDCT or limit its image quality. 
The position of the coronary arteries relative to AoA can also be assessed using invasive 
angiography which is often performed in most of the patients preoperatively in order to study 
coronary arteries and peripheral vessels. However, the angiographic procedure shows the bias due to 
its 2-dimensional nature and in some cases it may carry an high risk of complications. Therefore 
MDCT has been reported as a valid alternative to angiography. 9 
The role of echocardiography in the assessment of TAVI patients is well known. The 
incremental value of 3D echocardiographic technology and its accuracy in comparison to MDCT in the 
measurement of aortic annulus and ascending aorta dimensions have been also already 
demonstrated. 8,12,22 Otani et al. 23 evaluated 3DTEE AoA-LM in a large series of patients, however 3D 
accuracy in comparison with MDCT was calculated only in few cases, all without aortic valve stenosis. 
Unfortunately in aortic valve stenosis AoA-LM is generally shorter than in controls and the presence 
of leaflets and AoA calcifications may markedly impair the accuracy of 3DTEE measurements. 
Moreover, few postoperative data have been reported concerning the distance between left main 
and aortic prosthesis. 8 
The main findings and novelties of our study are twofold. Firstly, we demonstrated in a large 
series of aortic patients that a 3DTEE preoperatively estimation of AoA-LM distance is possible in 
most of them (97%). Only in 3 out of 122 cases LM was not adequately visualized due to poor quality 
of TEE images. AoA-LM measurement was accurate, comparable to MDCT data and highly 
reproducible on intra-observer and inter-observer variability. As expected patients with larger AoA 
dimensions had longer AoA-LM distance and for this reason larger prosthesis could be implanted 
without coronary impairment.  
The second important result is that 3DTEE allows an immediate evaluation of the distance 
between LM and aortic prosthesis after the implantation. This measurement is feasible in most of the 
cases (90%) and also accurate. In fact the 3DTEE computed prosthesis length (calculated as the 
difference between 3DTEE AoA-LM distance plus prosthesis- anterior mitral leaflet overlap, and the 
distance between LM and the prosthesis) is similar to the prosthetic nominal value. Interestingly in 16 
cases the upper edge of the prosthesis exceeded LM ostium, even though none of the enrolled 
patients had signs or symptoms of ischemia. These data are in accordance with the radiologic (MDCT) 
observation of Delgado et al. 8. A possible explanation is the limited extension of the overlap in our 
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cases (equal or <2 mm) involving a portion of prosthesis where its struts allows coronary inflow, 
without reaching the reinforced inferior part of the structure where the pericardial leaflets are 
inserted. 
No relation was found between the presence of prosthesis/left main overlap and the prosthesis 
size or the AoA-LM preoperative distance, supporting the importance of a correct implantation 
procedure, since even very small changes in the prosthesis positioning may interfere with the 
coronary flow. This result does not detract much from the necessity of an accurate evaluation of AoA-
LM distance. In fact, in high risk patients the knowledge of a small AoA-LM distance is an important 
information for the operator who may consequently adapt the prosthesis implantation. Indeed our 
data demonstrate the absence of a significant relation between prosthesis overlap and clinical 
variables as PPM or paravalvular AR. This observation reinforces the importance of a correct and 
precise knowledge of AoA-LM distance facilitating optimal and safe procedural maneuvers by the 
operator.  
Moreover after prosthesis deployment in the case of abrupt coronary artery occlusion, the 
preoperative awareness of a high occlusion risk may favorite the immediate recognition of this life-
threatening complication, inducing to a more prompt circulatory support and to the hemodynamic 
procedure of percutaneous recanalization in order to restore normal coronary flow. In this regard 
even though the LCC length has been postulated to be involved in this complication, in our patients 
we did not find prospectively any correlation between this measurement and AoA-LM.  
Conclusions 
Three dimensional TEE may estimates the AoA-LM distance as an alternative technique to 
MDCT. Pre and post 3DTEE data concerning the valve and prosthesis morphology and simultaneous 
real time evaluation of the aortic root including the LM coronary ostium give new insights regarding 
TAVI and its complications.  
Study limitations 
Even though we included in the study a high number of cases, only few patients received a 29 
mm prosthesis and for this reason the statistical analysis for this group has an important bias as 
shown in table 2 (no significant correlation was observed between 3DTEE and MDCT for Max-D and 
area of aortic annulus measurements). However the high correlation in the overall population 
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between 3DTEE and MDCT measurement confirms the value of 3-dimensional modality and the 
reported limitation does not detract much from our results. 
The right coronary artery was not evaluated in our study and we choose to focus our analysis 
only to the LM coronary ostium. Few data concerning the measurement by 2D TEE and not 3DTEE 
have been published regarding the measurement of the distance between right coronary ostium and 
aortic annulus (12), moreover right ostium is generally more distant from AoA in comparison with LM 
and its occlusion post-TAVI procedure is very uncommon. Right coronary artery imaging by real-time 
3DTEE is more difficult in comparison with the LM one. Even though the incidence of right coronary 
artery occlusion is low, future studies may define the role of 3DTEE particularly with the new 
technologies in the evaluation of both coronary ostia before and after TAVI.  
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Abstract  
Background. Post-procedural aortic regurgitation (AR) has been described in a large number of 
patients receiving transcatheter aortic valve implantation (TAVI). Objective The aim of this study was 
to examine the intraoperative 2-dimensional (2D) and 3-dimensional (3D) echocardiographic 
features of the aortic valve associated with significant post-procedural paravalvular AR. 
Methods. A total of 135 patients (81±7 years) with severe symptomatic aortic stenosis, who 
underwent TAVI, were imaged with comprehensive 2D and 3D transesophageal echocardiography 
before the procedure and peri-procedure. Various baseline and peri-procedural echocardiographic 
characteristics were tested to predict paravalvular AR post-TAVI: calcifications at the aortic valve 
commissures and leaflets, ‘aortic annulus eccentricity index’, ‘area cover index’, overlap between 
aortic prosthesis and anterior mitral leaflet. Post-procedural paravalvular AR≥2 was considered 
significant. 
Results. Successful TAVI was achieved in all patients. The incidence of paravalvular AR≥2 
mmediately after the procedure was 21% (28 patients). Commissural calcifications and, particularly, 
the calcification of the commissure between the right coronary and noncoronary cusps was 
significantly more frequent in presence of paravalvular AR; the area cover index pre-TAVI was 
significantly lower among patients with AR (11.1±11.8% vs 20.8±12.5%, p=0.0004). Multivariate 
analysis revealed that calcification of the commissure between the right coronary and non-coronary 
cusps (OR¼2.66, 95% CI 1.39 to 5.12, p=0.001), and the area cover index pre-TAVI (OR=0.95, 95% CI 
0.91 to 0.99, p=0.006) were the only independent predictors of significant paravalvular AR after 
TAVI. 
Conclusions. Intraoperative 2D and 3D transesophageal echocardiography identified 
calcification of the commissure between the right coronary and non-coronary cusps and the area 
cover index as independent predictors of significant paravalvular AR following TAVI. 
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Introduction 
Over the last few years, transcatheter aortic valve implantation (TAVI) has been demonstrated 
to be a feasible and effective therapeutic alternative to traditional aortic valve replacement for high-
risk surgical patients with symptomatic severe aortic stenosis. 1-7 Single- and multi-center studies 
showed significant improvements after TAVI in symptoms and quality of life together with excellent 
transvalvular haemodynamic characteristics and good survival rates at 2 years follow up. 5, 8, 9 
However, post-procedural aortic regurgitation (AR), mainly paravalvular, has been described in 
a relatively large number of patients after TAVI. 1-3, 5, 7-10 The majority of patients with paravalvular AR 
after TAVI shows mild grade regurgitation and the incidence of moderate or severe paravalvular AR is 
low (7% at 1 year and 6,9% at 2 years in the PARTNER trial).6 However, understanding the 
mechanisms and potential determinants of paravalvular AR after TAVI is of importance to minimize 
the incidence of this complication and therefore its potential impact on left ventricular (LV) 
performance and clinical outcome. 
Initial studies have proposed multi-detector computed tomography as a valuable imaging tool 
to achieve an accurate characterization of the aortic valve apparatus and to ensure high procedural 
success rate.11 However, in clinical practice, transesophageal echocardiography (TEE) is commonly the 
first imaging technique of choice to accurately characterize valvular morphology and geometry, both 
before and during the procedure, and to evaluate the results after TAVI. Therefore, the aim of this 
study was to identify potential predictors of significant paravalvular AR occurring immediately after 
TAVI, using intraoperative 2D and 3D TEE. 
Methods 
A total of 135 consecutive patients, who underwent TAVI with the Edwards-Sapien valve 
between November 2007 and January 2010 in 2 centers (Centro Cardiologico Monzino, IRCCS, Milan, 
Italy and Leiden University Medical Center, Leiden, The Netherlands), were included. TAVI was 
performed using the transfemoral or transapical approach, according to the peripheral artery 
anatomy. A 23-mm device was implanted when, as measured on 2D TEE images, the diameter of the 
aortic annulus (AoA) was > 18 mm and ≤ 21 mm, and a 26-mm device was implanted when the 
diameter of the AoA was > 21 mm and ≤ 25 mm. 
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Two-dimensional transthoracic echocardiography was performed before the procedure and 
before discharge to assess LV volumes and ejection fraction (EF), as well as to measure transaortic 
pressure gradients and aortic valve area normalized for body surface area (AVAi) according to current 
recommendations. 12 Aortic stenosis was defined as severe in the presence of a mean transaortic 
pressure gradient (MPG) greater than 40 mmHg or an AVAi < 0,6 cm2/m2 . 13, 14 
All patients were imaged with comprehensive peri-procedural 2D and 3D TEE, in the operating 
room. TEE was performed using the iE33 ultrasound system (Philips Medical Systems, MA) equipped 
with fully-sampled matrix-array 3D probe (model X7-2t) and various baseline and procedural variables 
were evaluated to predict significant paravalvular AR. All the measurements, based on 2D and 3D TEE, 
were performed intraoperatively. Pre-procedural measurements were obtained before prosthesis 
deployment, blind to the outcome of the procedure. 
2D transesophageal echocardiography  
Two-dimensional measurements of the AoA were performed, as recommended 15, during early 
systole in the long-axis view at approximately the 120° angle, at the hinge points of the leaflets. The 
presence and the distribution of aortic valve calcifications was evaluated in the short-axis view of the 
valve at approximately the 30°-60° angle. The amount of aortic calcifications was assessed, separately 
for the commissural and for the central regions of the cusps, using a semiquantitative score (0-4), as 
depicted in Figure 1: 0= no calcifications; 1= (minimal), speckles; 2= (mild) single nodule; 3= 
(moderate) two or more nodules; 4= (severe) diffuse, confluent calcifications. 16 A score was assigned 
to each cusp and commissure. An overall grade, ranging from 0 to 12, resulted from the sum of the 
three cusps and from the sum of the three commissures, respectively. Furthermore, whether the 
distribution of the calcifications was symmetric or not was noted. 
Aortic valve regurgitation, if present before the procedure, was recorded and quantified 
according to standard echocardiographic color-Doppler method (semiquantitative score: 0-4). 17 
After TAVI, aortic prosthesis overlap with the anterior mitral leaflet was measured at the 2D 
long-axis view as the length between the junction point of the prosthesis with the right sinus of 
Valsalva and the ventricular free edge of the prosthesis. 
The presence of post-procedural paravalvular AR was evaluated immediately after the device 
deployment and after removal of the catheter and the guidewire. Post-procedural paravalvular AR 
was quantified according to standard echocardiographic color-Doppler method using the jet width 
and extension and graded as: 0 (absent), 1 (mild), 2 (mild to moderate), 3 (moderate to severe), 4 
(severe). In the presence of multiple paravalvular AR jets, visualized in the short- and long-axis TEE 
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views, paraprosthetic, AR was expressed as an overall grade. Paravalvular AR was considered 
significant if ≥ 2. 
 
Figure 1. Examples of different degrees of aortic valve calcification assessed using a 
semiquantitative score: 1= minimal (panel A),  2= mild (panel B),  3= moderate (panel C), 4= 
severe calcifications (panel D). 
3D transesophageal echocardiography 
 Measurements on 3D datasets were obtained using the QLAB 3DQ software (Philips Medical 
System, Andover, MA, USA) available on the echocardiographic system. Three-dimensional 
measurements of the AoA were performed during early systole in a true cross sectional plane. In 
detail, 3D live and full volume images were acquired in order to obtain the visualization of a 
magnified aortic root in the 30° short-axis or the 120° long-axis view. The 3D datasets were cropped 
using two orthogonal planes through the long-axis of the LV outflow tract. A third transverse plane 
was positioned parallel and immediately below the aortic valve. This ensured a true “en face” view of 
the AoA, from which the shortest and the longest annulus diameters were measured. Annulus 
eccentricity was defined as 1 - the ratio between the shortest and the longest annulus diameter, so 
that a perfect circle has an eccentricity index of zero, while a higher eccentricity index represents a 
more elliptical geometry. Moreover in the same “en face” view, the annulus area was measured by 
planimetry. The "area cover index" was defined as the percentage difference between planimetered 
AoA area and the nominal prosthesis area (1 - annulus area/ prosthesis nominal area). The nominal 
prosthesis area was calculated on the basis of the pre-specified diameter of the available prosthesis 
(23 or 26 mm) supplied by the manufacturer (415 mm2 for a prosthetic diameter of 23 mm, 531 mm2 
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for the 26 mm diameter prosthesis). This index indicates a correspondence between the two areas 
when it is close to 0. When the planimetered aortic annular area is smaller compared to the nominal 
prosthesis area the cover index is higher. Figure 2 shows an example of the measurements of the 
native planimetered AoA in an 3D true cross-sectional plane. 
 
Figure 2. Measurements of the native planimetered aortic annulus in a 3D true cross sectional 
rendering pre-TAVI. Orthogonal diameters and planimetered area of the annulus (Panel A) are 
obtained through correct alignment based on 3D dataset. 
Moreover, immediately after the procedure in a 3D true cross-sectional plane of the aortic 
prosthesis at the level of the cusps, the device eccentricity index was calculated using the shortest 
and the longest diameter and the planimetered prosthesis area was traced adopting the internal 
dimensions of the prosthetic valve (Figure 3). In addition, the actual planimetered prosthesis area was 
compared both with the annulus planimetered area pre-TAVI (1-Planimetered 
Prosthesis/Planimetered Annulus) and with the prosthesis expected area calculated on the basis of 
the pre-specified diameter of the available prosthesis (1- Planimetered Prosthesis/ Prosthesis 
Nominal Area); the percentage difference was then recorded. 
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Figure 3. 3D aortic annulus after TAVI. Annulus measurements were performed after TAVI 
adopting the internal dimensions of the prosthetic valve and methods as in Figure 1. 
Statistical Analysis 
 Continuous data are presented as mean±SD and categorical variables as frequency or 
percentages, as appropriate. A normal distribution of continuous variables was assessed using the 
Kolmogorov-Smirnov test. Differences between patients with paravalvular AR<2 and patients with 
paravalvular AR≥2 were assessed with unpaired Student’s t test or Mann-Whitney U test for 
continuous variables, as appropriate, and with Chi-square test or Fisher’s exact test for categorical 
variables. Several clinical and echocardiographic characteristics pre-TAVI were tested in a univariate 
logistic regression analysis in order to evaluate whether some characteristics before the procedure 
could help predicting the development of significant AR after TAVI. Significant variables in univariate 
analysis were included in a multivariate logistic regression analysis with stepwise method for the 
identification of independent variables predicting paravalvular AR≥2. Goodness-of-fit was assessed 
using the Hosmer and Lemeshow test, in which a p value <0.05 indicated a lack of fit of the model. A p 
value <0.05 was considered statistically significant. All statistical analyses were performed using SPSS 
17.0 (SPSS Inc., Chicago, IL). 
Measurements were performed by two different operators, one per each involved Institution. 
The inter-observer variability has been assessed in terms of coefficient of variation (the ratio of 
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standard deviation of the differences to the mean value) and 95% limits of agreement at Bland-
Altman analysis between repeated measurements on a randomly chosen subset of 25 patients. 
Results 
Successful TAVI, defined as correct positioning and successful device deployment within the 
aortic valve without periprocedural major adverse cardiovascular and cerebral events, was reached in 
all patients. Paravalvular AR immediately post-TAVI was graded: 0 in 42 patients, 1 in 65 patients, 2 in 
25 patients, 3 in 2 patients and 4 in 1 patient. The incidence of paraprosthetic AR≥2 was 21% (28 
patients) immediately after the procedure. Of note, of the three patients with AR≥3 immediately after 
the procedure, one patient (AR=4) underwent the implantation of a second device, while in the 
remaining two patients balloon inflation was repeated and the maximal expansion of the valve was 
reached, with a significant decrease of paraprosthetic AR. 
AoA parameters were found to be highly reproducible on inter-observer variability (coefficient 
of variation: shorted diameter 4.9%, longest diameter 4.1%, planimetered area 8.8%). Moreover, the 
results of Bland-Altman analysis showed limited bias and narrow limits of agreement (shorted 
diameter: bias 0.9 mm – LOA: 2.7 mm, longest diameter bias 0.0 mm – LOA: 3.3 mm, AoA 
planimetered area bias 0.3 cm2 – LOA: 1.0 cm2) 
Baseline clinical and echocardiographic characteristics 
 Main clinical and echocardiographic characteristics of the overall patient population and for 
each group (according to the presence of post-TAVI paravalvular AR<2 and AR≥2) are listed in Table 1. 
Clinical parameters did not show significant differences among the 2 groups. All patients had severe 
aortic stenosis (AVAi 0.38±0.10 cm2/m2, MPG 47±16 mmHg). The AR grade before TAVI was similar 
between the study groups. In addition, LV volumes and EF were not significantly different between 
the groups. The mean annulus eccentricity index pre-TAVI was 0.11±0.08 and the mean “area cover 
index” was 18.5±13.0%. A trend towards a higher annulus eccentricity index was observed among 
patients with significant paravalvular AR and the “area cover index” was significantly lower among 
patients with significant paravalvular AR. 
The total amount of commissural calcifications, measured semi-quantitatively, was 
respectively: 0-4 in 13%, 5-8 in 74%, 9-12 in 13% of the patients. The total amount of commissural 
calcifications was significantly higher among patients with significant paravalvular AR ≥ 2 (Table 1). 
The commissure between the right coronary and non-coronary cusps was the most heavily calcified in 
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24% of cases and was more frequently calcified among subjects with AR ≥ 2 (p<0.05). The amount of 
central calcifications was 0-4 in 16% of the patients, 5-8 in 62% of the cases and 9-12 in 22% of the 
aortic valves. In 24% of the aortic valves the non-coronary cusp was the most calcified, followed by 
the right coronary (14%) and left coronary cusp (9%). Twenty-two percent showed a symmetric 
distribution of valve calcifications in all the three cusps (Table 1). 
Table 1. Baseline clinical and echocardiographic characteristics together with pre-procedural 
amount and distribution of aortic valve calcifications of the whole population, and separately 
for patients without and with significant paravalvular aortic regurgitation (AR). 
Variables Overall 
(n=135) 
AR < 2 
(n=107) 
AR ≥ 2 
(n=28) 
p-value 
Age (years) 81±7 81±7 81±8 0.982 
Sex (male) 61 (45%) 44 (41%) 17 (61%) 0.064 
Body surface area (m
2
) 1.8±0.2 1.8±0.2 1.8±0.2 0.899 
Logistic EuroSCORE (%) 22.3±12.9 23.7±14.3 18.0±5.1 0.136 
STS score 9.9±8.7 10.3±9.2 8.1±6.2 0.427 
Angina 19 (29%) 16 (31%) 3 (21%) 0.741 
Dyspnoea 60 (91%) 47 (90%) 13 (93%) 1.000 
Syncope 20 (30%) 16 (31%) 4 (29%) 1.000 
CAD 36 (54%) 29 (56%) 7 (50%) 0.768 
Previous CABG 9 (14%) 9 (17%) 0 (0%) 0.186 
Previous PCI 16 (24%) 14 (27%) 2 (14%) 0.488 
Previous MI 12 (18%) 11 (21%) 1 (7%) 0.436 
HBP 59 (89%) 46 (88%) 13 (93%) 1.000 
Hcholest 34 (52%) 27 (52%) 7 (50%) 1.000 
Diabetes Mellitus 17 (26%) 13 (25%) 4 (29%) 0.744 
PVD 26 (39%) 20 (38%) 6 (39%) 0.768 
Smoking 23 (35%) 18 (35%) 5 (36%) 1.000 
Atrial Fibrillation 8 (12%) 7 (13%) 1 (7%) 1.000 
Paced at baseline 5 (8%) 4 (8%) 1 (7%) 1.000 
LV EDVi PRE (mL/m
2 
) 61±22 60±21 64±24 0.378 
LV ESVi PRE (mL/m
2 
) 29±18 28±18 33±20 0.273 
EF PRE (%) 55±12 55±13 52±12 0.136 
AVAi PRE (cm
2
/m
2
) 0.38±0.10 0.38±0.10 0.37±0.08 0.678 
AO MPG PRE (mmHg) 47±16 47±16 48±18 0.786 
AO regurgitation PRE (0-4) 1.01±0.79 0.99±0.84 1.11±0.57 0.490 
Annulus TEE (mm) 22±2 22±2 22±2 0.393 
Annulus eccentricity index PRE 0.11±0.08 0.11±0.08 0.12±0.07 0.067 
Area cover index PRE (%) 18.5±13.0 20.8±12.5 11.1±11.8 0.0004 
Continue 
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Variables Overall 
(n=135) 
AR < 2 
(n=107) 
AR ≥ 2 
(n=28) 
p-value 
Commissural calcifications    0.013 
0-4 18 (13%) 16 (15%) 2 (7%)  
5-8 100 (74%) 82 (77%) 18 (64%)  
9-12 17 (13%) 9 (8%) 8 (29%)  
Central calcifications    0.121 
0-4 22 (16%) 20 (19%) 1 (4%)  
5-8 84 (62%) 66 (62%) 19 (68%)  
9-12 29 (22%) 21 (19%) 8 (28%)  
Most Calcified Commissure %     
Symmetric calcification without 
commissure accentuation 
72 (53%) 55 (51%) 17 (61%) 0.38 
Non coronary - Left coronary cusp 16 (12%) 16 (15%) 0 (0%) 0.28 
Non coronary - Right coronary cusp 32 (24%) 21 (20%) 11 (39%) <0.001 
Left coronary - Right coronary cusp 15 (11%) 15 (14%) 0 (0%) 0.17 
Most Calcified Cusp %     
Symmetric calcification without cusp 
accentuation 
72 (53%) 59 (55%) 13 (46%) 0.41 
Non coronary cusp 32 (24%) 25 (24%) 7 (25%) 0.26 
Left coronary cusp 12 (9%) 9 (8%) 3 (11%) 0.67 
Right coronary cusp 19 (14%) 14 (13%) 5 (18%) 0.15 
Data are expressed as mean 6 SD for continuous variables or as number (percentage) for categorical 
data; p value for comparison between AR <2 and AR ≥2. AO, aortic; AVAi, indexed aortic valve area; CAD, 
coronary artery disease; CABG, coronary artery bypass grafting; EF, ejection fraction; HBP, high blood 
pressure; Hcholest, hypercholesterolaemia; LV EDVi, indexed left ventricular end-diastolic volume; LV 
ESVi, indexed left ventricular end-systolic volume; MI, myocardial infarction; MPG, mean pressure 
gradient; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; TEE, 
transesophageal echocardiography. 
Echocardiographic characteristics after TAVI 
 TAVI was performed through the transfemoral approach in 69 patients (51%) and through the 
transapical access in 66 patients (49%). Out of 135 patients, 47 patients (35%) received a 23-mm 
valve, while 88 patients (65%) received a 26-mm valve; there was no difference regarding valve size 
between the two groups with and without significant paravalvular AR. As shown in Table 2, all 
patients showed improvements in transvalvular hemodynamics (AVAi 1.14±0.26 cm2/m2, MPG 11±4 
mmHg). 
After TAVI, AoA eccentricity index decreased (0.06±0.05) (Table 2). The mean prosthesis 
planimetered area post-TAVI was 323±52 mm2 in patients with a 23-mm device and 385±50 mm2 in 
patients with a 26-mm device. The prosthesis planimetered area post-TAVI was 7.3±17.4% smaller 
than the native annulus area pre-TAVI; this percentage difference was similar among subjects with 
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and without AR. The difference between the planimetered prosthesis area and the nominal 
prosthesis area was significantly lower in presence of paravalvular AR≥2, suggesting a certain degree 
of undersizing of the prosthesis despite proper expansion of the device. In addition, the length of 
aortic prosthesis overlap with anterior mitral leaflet was 5±2 mm, without any significant difference 
between the two groups.  
Table 2. Echocardiographic characteristics after TAVI. 
Variables Overall 
(n=135) 
AR < 2 
(n=107) 
AR ≥ 2 
(n=28) 
p-value 
LV EDVi POST (mL/m
2 
) 58±26 56±26 61±22 0.126 
LV ESVi POST (mL/m
2 
) 27±19 26±19 35±18 0.602 
EF POST (%) 56±11 57±11 51±11 0.073 
AVAi POST (cm
2
/m
2
) 1.14±0.26 1.15±0.27 1.11±0.21 0.319 
AO MPG POST (mmHg) 11±4 11±5 10±4 0.734 
Annulus eccentricity index POST 0.06±0.05 0.06±0.05 0.05±0.04 0.686 
1-Planimetered Prosthesis/Planimetered 
Annulus 
7.3±17.4 7.6±15.1 6.4±23.3 0.637 
1-Planimetered Prosthesis/Prosthesis 
Nominal Area 
25.8±10.7 27.9±8.5 18.6±4.0 0.002 
Prosthesis overlapping (mm) with MV 5±2 5±2 5±1 0.766 
Data are expressed as mean 6 SD or median (258 percentilee758 percentile) for continuous variables; p 
value for comparison between AR <2 and AR ≥2. AO, aortic; AR, aortic regurgitation; AVAi, indexed aortic 
valve area; MPG, mean pressure gradient; MV, mitral valve. 
Determinants of paravalvular AR 
 At the logistic regression analysis, the pre-TAVI univariate determinants of paravalvular AR≥2 
post-TAVI were the degree of the commissural calcifications of the native valve, the calcification of 
the commissure between the right and the non-coronary cusps and the “area cover index” pre-TAVI. 
Multivariate analysis revealed that calcification of the commissure between the right coronary and 
non-coronary cusp (OR=2.66, 95%CI, p=0.001) and the area cover index pre-TAVI (OR=0.95, 95% CI, 
p=0.006) were the only independent predictors of the presence of significant paravalvular AR 
(R2=0.52). The model displayed satisfactory goodness-of-fit (p=0.26). 
Discussion 
The main findings of the current study are the following: a) 3D-TEE allows a complete and 
detailed evaluation of the anatomy of the aortic valve apparatus before the procedure, as well as of 
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the prosthetic valve immediately after TAVI, b) the degree of calcification, particularly of the 
commissure between the right coronary and non-coronary cusps, and “area cover index” represent 
independent predictors of significant paravalvular AR.  
Many trials have shown that TAVI is feasible and provides haemodynamic and clinical 
improvement in high-risk patients with symptomatic severe aortic stenosis. 3,5,8-10 However, the 
development of post-procedural paravalvular AR is one of the most frequent complications after 
TAVI. Although previous studies showed that paravalvular AR was mild in the majority of cases 1,5, the 
long-term consequences of paravalvular leaks are not well-established. 18-21 Significant paravalvular 
AR post-TAVI may be due to several factors, including device malpositioning, erroneous device sizing 
and presence of severely calcified native valves. 11, 22, 23 Therefore, the analysis of the mechanisms and 
the identification of potential determinants of significant paravalvular AR post-TAVI is important to 
prevent the occurrence of this complication.  
Aortic valve calcifications 
 Incomplete device expansion due to aortic valve calcifications is believed to be one of the 
contributing factors to paravalvular AR post-TAVI. 23 In fact, heavily calcified native aortic valves may 
not allow a perfect apposition of the device along the annulus circumference. This has been 
demonstrated in experimental series and in clinical series by using multi-detector computed 
tomography. 24-26 Delgado et al.11  found that patients with moderate aortic regurgitation post-TAVI 
showed more calcified native valves, as quantified by Agatston calcium score, in particular at the level 
of the commissures. Koos et al.24 emphasized that patients with severe aortic valve calcification had 
an increased risk of significant paravalvular AR as well as a trend of an increased need for second 
transcatheter maneuvers (re-ballooning) after TAVI. Moreover, Zegdi et al.26, trying to define the 
precise characteristics of a self-expandable aortic stent deployment in humans, found that stent 
misdeployment, with a triangular or elliptical shape, occurred in one-third of cases of tricuspid valves; 
in these patients a gap between the external surface of the stent and the inner surface of the native 
aortic valve was identified and located exclusively at the level of the commissures; this may occur 
when part of the stent frame lies on top of a large calcification. Our results, based on intra-operative 
3D TEE, confirm these previous findings, showing that the calcifications of the commissure between 
the right coronary and non-coronary cusp is related to significant post-procedural paravalvular AR. 
Area cover index 
 Current recommendations include echocardiography as a valuable method to size the AoA 
diameter and to select the correct prosthesis size.8 Although caution was recommended regarding 
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the underestimation of the annular cross-sectional area, due to its elliptical geometry, no suggestions 
were provided to overcome this problem. 3D TEE, as previously reported by Ng et al. 27, allows a 
direct tracing the planimetered area of the AoA without geometric assumptions: despite a 3D 
underestimation of annulus area compared to the same measurement performed with computed 
tomography, considered as the gold standard, a good correlation with narrow limits of agreement 
was found between the two methods.  
Considering the fact that the 3D echocardiographic measurement of the AoA is feasible and 
accurate, we tried to identify a relationship between the planimetered annular area, the nominal 
prosthesis expected area and the presence of post-TAVI paravalvular AR. The area cover index pre-
TAVI was significantly lower among patients with significant post-procedural paravalvular AR, 
suggesting that a certain degree of prosthesis oversizing is needed to ensure a good procedural 
result. Similarly, Detaint et al. 28 found a significant relationship between large annulus size and the 
occurrence of significant paravalvular AR; to appraise the congruence between annulus and device 
they used a “cover index” that compared 2D echocardiographic AoA diameter and prosthesis 
diameter and found a significant relationship between low cover index and AR. 
In addition, the multivariate logistic regression analysis performed in this study demonstrated 
that, calcification of the commissure between the right coronary and non-coronary cusp and a low 
“area cover index” pre-TAVI were also independent and reliable predictor of post-procedural 
significant paravalvular AR. Therefore, important morphological aspects, related to the severity as 
well as the localization of valvular calcification, may play a role in the development of paravalvular 
aortic regurgitation, leading to an abnormal deployment of the prosthesis in terms of irregular shape 
or inadequate adhesion of the prosthesis itself to the native valve. Moreover, a low “area cover 
index” predicts the development of significant post-procedural paravalvular AR suggesting that this 
index could be utilized as an additional parameter when choosing the prosthetic size in all those 
patients with borderline 2D TEE annulus size. The “area cover index” and the availability of larger 
prostheses may reduce the incidence of significant paravalvular AR, avoiding prosthetic undersizing 
and simultaneously allowing a better fit. 
Evaluation of prosthesis deployment with 3D TEE 
 To date, few studies have evaluated the deployment characteristics of the transcatheter 
bioprosthesis. 11,27,28 In this field 3D TEE may provide a good visualization of the device, allowing the 
assessment of the quality of its expansion and its positioning with respect to near structures. Our 
data demonstrated that a 3D TEE morphological evaluation of the device post TAVI was feasible in 
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135 patients in a routine clinical setting, allowing the assessment of several parameters. Among our 
135 patients the mean prosthesis planimetered area post-TAVI was 323±52 mm2 and 385±50 mm2 in 
patients with a 23 mm and 26 mm device, respectively. The prosthesis planimetered area post-TAVI 
was approximately 7.3±17.4% smaller than the native annulus area pre-TAVI in the whole population 
(and with no differences between patients with and without significant paravalvular AR), suggesting a 
satisfactory prosthesis deployment. Despite the successful deployment, the prosthesis planimetered 
area remained smaller than the annulus area pre TAVI mainly because the actual dimension of the 
device expansion is limited by the annular stiffness and the severity of cusps and commissural 
calcifications. Moreover, the implanted prosthesis does not reach “in vivo” the expected nominal 
area as previouslty described.29 In the current study, the difference between planimetered and 
nominal prosthesis area was significantly lower in patients with paravalvular AR ≥ 2 compared to 
patients without regurgitation, suggesting a proper deployment of a relatively undersized device. 
Study limitations 
 This study considers only the balloon-expandable valve. However, the aim of this study was 
not to compare the echocardiographic predictors of aortic regurgitation in different devices. In 
addition, the precise quantification of aortic regurgitation following TAVI is still problematic and relies 
only on color-Doppler imaging; further studies are needed to clarify this topic. Furthermore, only a 
limited number of variables pre-procedure were tested in the regression analysis, given the relatively 
few cases with significant AR. In the present series, patients with paravalvular AR have asymmetrically 
calcified valves with a high frequency of calcification of the commissure between the right coronary 
and non-coronary cusp. However, the relatively limited number of patients with significant 
paravalvalvular AR preclude us to observe significant differences in terms of other location of 
calcifications. 
Finally, a limitation of this study could be the absence of a comparison between 3D TEE AoA 
measurements and respective values obtained in the same subjects from other 3D radiologic 
technique, such as computed tomography. However, the assessment of the accuracy of 3D TEE 
imaging versus other techniques was beyond the scopes of this study, which was based on the most 
widely available imaging approach, also feasible in the operatory theatre. 
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Conclusions 
This study suggests that intraoperative 2D and 3D TEE may allow the identification of predictors 
of significant paravalvular AR following successful TAVI. In particular, the presence of heavily calcified 
commissure between the right coronary and non-coronary cusp and the measurement of “area cover 
index” should be considered during patient selection for TAVI in order to minimize the development 
of significant paravalvular AR after the procedure. 
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Abstract 
Background. Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in 
high-risk patients with severe aortic stenosis. Aortic annulus (AoA) sizing is crucial for TAVI success. 
The aim of the study was to compare AoA dimensions measured by multidetector computed 
tomography (MDCT) vs those obtained with transthoracic (TTE) and transesophageal 
echocardiography (TEE) for predicting paravalvular aortic regurgitation (PAR) after TAVI.  
Methods. Aortic annulus maximum diameter, minimum diameter, and area were assessed 
using MDCT and compared with TTE and TEE diameter and area for predicting PAR after TAVI in 151 
patients (45 men, age 81.2±6.4 years).  
Results. Aortic annulus maximum, minimum diameter, and area detected by MDCT were 
25.04±2.39 mm, 21.27±2.10 mm, and 420.87±76.10 mm2, respectively. Aortic annulus diameter and 
area measured by TTE and TEE were 21.14±1.94 mm and 353.82±64.57 mm2 and 22.04±1.94 mm 
and 384.33±67.30 mm2, respectively. A good correlation was found between AoA diameters and 
area evaluated by MDCT vs TTE and TEE (0.61, 0.65, and 0.69 and 0.61, 0.65, and 0.70, respectively), 
with a mean difference of 3.90±1.98 mm, 0.13±1.67 mm, and 67.05±55.87 mm2 and 3.0±2.0 mm, 
0.77±1.70 mm, and 36.54±56.43 mm2, respectively. Grade ≥2 PAR occurred in 46 patients and was 
related to male gender, higher body mass index, preprocedural aortic regurgitation, and lower 
mismatch between the nominal area of the implanted prosthesis and AoA area detected by MDCT. 
Conclusions. Mismatch between prosthesis area and AoA area detected by MDCT is a better 
predictor of PAR as compared with echocardiography mismatch. Specific MDCT-based sizing 
recommendations should be developed. 
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Introduction 
After many years of research and development, transcatheter aortic valve implantation (TAVI) 
has become a reproducible and effective alternative to conventional aortic valve replacement for 
patients with severe and symptomatic aortic stenosis (AS) who are considered to be at high surgical 
risk. Despite being less invasive, TAVI may be associated with serious complications. Among them, 
moderate to severe para-valvular regurgitation (PAR) occurs in 7% to 20% of patients 1-4 and is 
associated with increased in-hospital and late mortality. The negative impact of moderate to severe 
PAR on clinical outcome is a compelling motivation to perform studies for assessing anatomic and 
procedural-related predictors of this complication in order to guide patient evaluation before and 
during TAVI. Transthoracic (TTE) and transesophageal echocardiography (TEE) have been used for 
aortic annulus (AoA) measurement in order to choose a prosthesis of appropriate size. 5, 6 However, 
prosthesis sizing with both imaging techniques is based on the assumption that AoA has a circular 
shape. On the contrary, recent studies with multidetector computed tomography (MDCT) 
demonstrated that AoA is frequently elliptical. 7-10 Moreover, TTE and TEE may underestimate AoA 
size as compared to MDCT.8, 11 Therefore, we sought to compare the measurement of AoA area by 
MDCT using planes transecting the axis of the aortic root versus AoA evaluation by TTE and TEE based 
on the geometrical assumption that AoA is circular and to assess their relationship with PAR after 
TAVI in patients treated with the Sapien prosthesis. 
Methods 
Between April 2008 and April 2011, 260 consecutive patients with severe AS were referred to 
our institute for TAVI. In 11 patients (7%), TAVI was not performed because of contraindications, 
while 3 (2%) patients were treated with surgical valve replacement due to complications occurring 
during the percutaneous procedure.  
Exclusion criteria for MDCT prior to TAVI were severe impaired renal function (creatinine 
clearance <30 ml/min), inability to sustain a 10-s breath hold, atrial fibrillation or other cardiac 
arrhythmias, and heart rate (HR) 70 bpm despite an oral dose of ivabradine (10 mg/die for 24-48 
hours before MDCT) administered in patients with a resting HR ≥70 bpm. According to the exclusion 
criteria, 47 (18%) patients did not undergo MDCT, while MDCT evaluation was performed without 
ECG gating in 48 patients (18%), respectively. Thus, a total of 151 patients were included in the study 
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(45 men, mean age 81.26.4 years). Written informed consent was obtained from all patients and the 
study protocol was approved by the local ethical committee. 
Echocardiography protocol 
In all patients, TTE was obtained using a commercially available system (IE33 system, Philips 
Medical System, MA) at baseline and after TAVI.  For each patient, end-diastolic (EDV), end-systolic 
(ESV) left ventricle volumes and ejection fraction (EF) were measured.. The severity of AS was 
assessed by the peak and mean aortic gradients, while the aortic valve area was calculated with the 
continuity equation. AS was graded according to the American College of Cardiology/American Heart 
Association guidelines.12 
 Aortic regurgitation was graded as none (grade 0), mild (grade 1), mild to moderate (grade 2), 
moderate (grade 3) or severe (grade 4) according to published guidelines. 12  
Measurement of AoA-diameter (AoA-D) by TTE and TEE were performed in systole in a 
parasternal long-axis view on the left ventricular outflow tract at the point of insertion of the right 
and non-coronary aortic leaflets (Figure 1A and 1B). The AoA-area was estimated using the following 
equation (AoA-DTTE/2)
2* with the assumption that they are circular. PAR was assessed immediately 
following valve implantation and thereafter at 30 days. It was classified into 4 grades as previously 
described. 12 PAR 2/4 was defined as significant.  
To evaluate whether a wrong positioning of the prosthesis could be the cause of PAR, the final 
position of the valve was assessed reviewing TEE and fluoroscopy images in all patients with PAR2. A 
wrong position was identified when the inflow of prosthesis was above the basal insertion of the 
native leaflets or when the outflow portion of the sealing cuff was above the basal insertion of the 
native leaflets.  
Patient-prosthesis mismatch was defined as the difference between the prosthesis area and 
both AoA-area measured by TTE and TEE. To appraise the congruence between the AoA and device a 
“cover index” expressed as a ratio of: 100x[(prosthesis area – TTE and TEE area)]/prosthesis area was 
measured as well. 
MDCT protocol 
The MDCT exams were performed with a LightSpeed VCT XT or Discovery HD750 scanner (GE 
Healthcare, Milwaukee, WI) with the slice configuration 64 x 0.625 mm. All patients received a triple-
injection protocol of an 80-ml bolus of contrast (Iomeron 400 mg/ml, Bracco, Milan, Italy) through an 
antecubital vein at an infusion rate of 5 ml/s, followed by 50 ml of saline solution and an additional 
50-ml contrast bolus at 3.5 ml/s using fluoroscopic trigger method.  
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AoA was defined as a virtual ring formed by joining the basal attachments of the aortic leaflets. 
13 For each AoA, maximum diameter, minimum diameter and area were measured in systole in an 
orthogonal plane on the center line of the aorta. (Figure 1 Panel C to E).  
Finally, patient-prosthesis mismatch was defined as the difference between the nominal area 
of the prosthesis implanted and the AoA-area derived by maximum and minimum diameters using 
the following equation (AoA-DTTE/2)
2* with the assumption that they are circular or versus the AoA-
area directly measured by MDCT. The congruence between the AoA and device a “cover index” 
expressed as a ratio of: 100x[(prosthesis area – MDTC area)]/prosthesis area was estimated as well.  
Each MDCT variable was measured twice by one of the investigators (GP), while another 
blinded reader (GB) measured the same MDCT variables once again to test the intra-observer and 
inter-observer variability. 
 
Figure 1. Methodology for the assessment of the AoA. A, TTE: the AoA-D was measured in mid-
systole by TTE (AoA-DTTE) in a parasternal long-axis view on the left ventricular outflow tract at 
the point of insertion of the right and non-coronary aortic leaflets. B, TEE: the AoA-D was 
measured in mid-systole by TEE (AoA-DTEE) in the mid-esophageal  long-axis view (120° to 140°) 
on the left ventricular outflow tract at the point of insertion of the right and non-coronary 
aortic leaflets. C-E, MDCT: the AoA evaluated by MDCT (AoAMDCT) was defined as a virtual ring 
formed by joining the basal attachments of the aortic leaflets. AoAMDCT maximum diameter 
(AoA-DMaxMDCT), minimum diameter (AoA-DMinMDCT) and area (AoA-AMDCT) were measured in 
an orthogonal plane on the center-line of the aorta obtained in oblique coronal and oblique 
sagital views, respectively. 
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TAVI procedure 
All procedures were performed by a combined team of cardiologists, cardiac surgeons and 
anesthesiologists working together in a dedicated hybrid room in general anesthesia. The Sapien 
valve (Edwards Lifesciences Inc, Irvine, CA) in three different sizes (23-mm, 26-mm and 29-mm 
expanded diameter) was used in all patients. The final choice of the prosthesis size was made 
according to guidelines 14, while the transfemoral or transapical approach was chosen on the basis of 
aorta and peripheral artery evaluation by MDCT.  
Statistical Analysis 
Statistical analysis was performed with the SPSS version 17.0 software (SPSS Inc., Chicago, Il). 
Continuous variables were expressed as mean±SD, and discrete variables were expressed as absolute 
numbers and percentages. The intra-observer and inter-observer variability for the evaluation of AoA-
DMaxMDCT, AoA-DMinMDCT and AoA-AMDCT were tested with Cohen’s Kappa. Student t test was used to 
test differences of continuous variables between the baseline and post-TAVI parameters. Regarding 
AoA-D and Ao-A, the Spearman’s correlation and Bland-Altman analysis were used to compare MDCT 
vs. TTE and TEE. Variables were included in a multivariate logistic regression. The receiver-operating 
characteristic curve for mismatch between prosthesis and AoA size evaluated by different imaging 
modalities (i.e., a plot of sensitivity against 1-specificity for each cut-off value) was plotted to 
measure the area under the curve expressed as c-value and to reach the best mismatch cut-off to 
predict PAR. P value <0.05 and C value >0.5 were considered statistically significant. 
No extramural funding was used to support this work. The authors are solely responsible for 
the design and conduct of this study, all study analyses, the drafting and editing of the paper and its 
final contents. 
 Results 
Clinical characteristics, echocardiography and MDCT findings of the study patients at baseline 
and after TAVI are summarized in Table 1. All patients had severe AS (indexed aortic valve area 
0.380.09 cm2/m2). The preprocedure aortic regurgitation was scored as grade 0, 1, 2, 3 and 4 in 114 
(75.5%), 23 (25.2%), 8 (5.3%), 5 (3.3%) and 0 (0%) patients, respectively. AoA-diameter and area 
measured by TTE and TEE were 21.14±1.94 mm, 22.04±1.94 mm, 353.82±64.57 mm2 and 
384.33±67.30 mm2, respectively. AoA-maximum and minimum diamaters and AoA-area evaluated by 
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MDCT were 25.042.39 mm, 21.272.10 mm and 420.8776.10 mm2, respectively, with a low intra-
observer and inter-observer variability (K: 0.95 and 0.94).  
Table 1. Baseline characteristics of the study population. 
Variables Baseline Post- TAVI p-value 
Clinical characteritics    
Number of patients, n 151   
Gender (male/female) 45/106   
Age (y), mean±SD 81.16±6.36   
BMI (Kg/m
2
), mean±SD 25.63±4.71   
BSA (m
2
), mean±SD   1.73±0.2   
Logistic Euroscore, mean±SD 20.8±10   
Echocardiographic characteristics    
EDV/BSA (mL/m
2
), mean±SD   56.73±20.59 54.48±20.18 .05 
ESV/BSA (mL/m
2
), mean±SD   21.53±14.44 24.28±20.23 .03 
EF (%), mean±SD   58.66±11.61 64.25±50.64 NS 
Peak aortic gradient (mmHg) 87.17±21.36 21.70±7.41 .0001 
Mean aortic gradient (mmHg) 53.70±14.40 11.69±4.39 .0001 
Aortic valve area/BSA (cm
2
/m
2
) 0.38±0.09 1.30±0.33 .0001 
Preprocedural aortic regurgitation (0-4) 0.39±0.89 0.38±0.63 NS 
Pulmonary pressure (mmHg) 41.07±11.17 34.43±8.72 .0001 
AoA-DTTE (mm), mean±SD   21.14±1.94   
AoA-ATTE (mm
2
), mean±SD   353.82±64.57   
AoA-DTEE (mm), mean±SD   22.04±1.94   
AoA-ATEE (mm
2
), mean±SD   384.33±67.30   
MDCT characteristics    
AoA-DMaxMDCT (mm), mean±SD   25.04±2.39   
AoA-DMinMDCT (mm), mean±SD   21.27±2.10   
AoA-AMDCT (mm
2
), mean±SD   420.87±76.10   
Intraobserver variability 0.95   
Interobserver variability 0.94   
TAVI    
Transapical (23/26/29 mm), n 94 (44/46/4)   
Transfemoral (23/26/29 mm), n 57 (33/24/0)   
Mismatch    
AoA-ATTE mismatch (mm
2
), mean±SD   121.42±49.16*   
AoA-ATEE mismatch (mm
2
), mean±SD   90.91±50.28*   
AoA-AMDCT mismatch (mm
2
), mean±SD   −21.36±70.41   
AoA-AMDCT, AoA-A measured by MDCT; AoA-ATEE, AoA-A measured by TEE; AoA-DMaxMDCT, 
maximum AoA-D measured by MDCT; AoA-DMinMDCT, minimum AoA-D measured by MDCT; AoA-DTEE, 
AoA-D measured by TEE; BMI, body mass index; BSA, body surface area; NS, not significant. * P < .001 vs 
mismatch for AoA-A measured by MDCT 
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The Pearson’s correlation and Bland-Altman analysis are shown in figure 2 and 3. 
 
 
Figure 2. Pearson’s correlation (upper panels) and Bland-Altman analysis (lower panel) 
between multidetector computed tomography (MDCT) and transthoracic echocardiography 
(TTE) assessment of aortic annulus diameter (AoA-D) and area (AoA-A). AoA-AMDCT: aortic 
annulus area measured by MDCT; AoA-ATTE: aortic annulus area measured by TTE; AoA-DTTE: 
aortic annulus diameter measured by TTE; AoA-DMaxMDCT: maximum aortic annulus diameter 
measured by MDCT; AoA-DMinMDCT: minimum aortic annulus diameter measured by MDCT.  
TAVI was performed with a transfemoral or a transapical approach in 57 and 94 of them, 
respectively. A 23-mm Sapien valve was used in 77 (51%) patients, a 26-mm valve in 70 (46%) patients 
and a 29-mm valve in 4 (3%) patients, respectively. Procedural success was 100% without intra-
operative mortality. After TAVI, peak and mean aortic gradients and pulmonary artery pressure 
decreased (p<0.0001) and aortic valve area increased (p<0.0001). The mismatch between the area of 
the implanted valve and the AoA-area measured by MDCT was lower than the mismatch between the 
AoA-area evaluated by TTE and TEE  (-21.3670.41 mm2 versus 121.4249.16 mm2 and 90.9150.28 
mm2, respectively, p<0.01).  
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Figure 3. Pearson’s correlation (upper panels) and Bland-Altman analysis (lower panel) 
between multidetector computed tomography (MDCT) and transesophageal echocardiography 
(TEE) assessment of aortic annulus diameter (AoA-D) and area (AoA-A). AoA-AMDCT: aortic 
annulus area measured by MDCT; AoA-ATEE: aortic annulus area measured by TEE; AoA-DTEE: 
aortic annulus diameter measured by TEE; AoA-DMaxMDCT: maximum aortic annulus diameter 
measured by MDCT; AoA-DMinMDCT: minimum aortic annulus diameter measured by MDCT.  
Assessment of PAR showed no leakage in 58 (38%) patients, mild in 47 (31%) patients, mild to 
moderate in 26 (17%) patients, moderate to severe in 19 (13%) patients and severe in 1 (1%) patient 
immediately following valve implantation. At 30 days, 51 (34%), 54 (36%), 23 (15%), 22 (14%) and 1 
(1%) patients showed PAR grade 0, 1, 2. 3 and 4, respectively. Therefore, significant PAR (≥2) occurred 
in 46 (30%) patients immediately after TAVI and at 30 days as well. According to the pre-TAVI intra-
aortic regurgitation, a significant PAR (2) occurred in 27  (23.7%), 13 (56.5%), 2 (25%) and 4 (80%) 
patients with grade 0, 1, 2 and 3, respectively. As showed in Table 2, PAR was related to male sex 
(p=0.0005), high body mass index (p=0.05), higher pre-procedural aortic regurgitation (p=0.01),lower 
mismatch and cover index measured by MDCT (p=0.0093 and 0.0050, respectively). On the contrary, 
no difference was found in terms of cover index measured by TTE and TEE between patients with 
PAR<2 versus those with PAR 2.  
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Table 2. Determinants of postprocedural PAR. 
Variables AR < 2/4  
(n = 105) 
AR = 2/4 
(n=46) 
p-value ROC 
(c 
value) 
Clinical characteritics     
Male/female, n (%) 22 (21)/83 (79) 23 (50)/23 (50) <0.01 0.65 
Age (y), mean±SD 80.88±6.69 81.80±5.54 0.41 0.54 
BMI (Kg/m
2
), mean±SD 26.13±4.70 24.49±4.56 0.05 0.60 
Echocardiographic characteristics     
EDV/BSA (mL/m
2
), mean±SD   56.99±21.84 56.15±17.70 0.82 0.50 
ESV/BSA (mL/m
2
), mean±SD   20.64±13.96 23.50±15.40 0.28 0.59 
EF (%), mean±SD   58.87±12.29 58.18±9.98 0.74 0.55 
Peak aortic gradient (mmHg) 87.83±21.31 85.67±21.62 0.57 0.53 
Mean aortic gradient (mmHg) 54.12±14.40 52.74±14.48 0.59 0.51 
Aortic valve area/BSA (cm
2
/m
2
) 0.37±0.09 0.40±0.09 0.06 0.60 
Preprocedural aortic regurgitation (0-4) 0.28±0.70 0.65±0.99 0.01 0.62 
Pulmonary pressure (mmHg) 41.33±11.57 40.48±10.27 0.67 0.54 
AoA-DTTE (mm), mean±SD   21.01±1.94 21.45±1.89 0.20 0.57 
AoA-ATTE (mm
2
), mean±SD   349.45±65.14 363.80±62.78 0.21 0.57 
AoA-ATE mismatch (mm
2
), mean±SD 124.46±50.23 114.48±46.38 0.25 0.55 
AoA-ATTE cover index (%), mean±SD 26.19±9.82 23.88±9.53 0.18 0.57 
AoA-DTEE (mm), mean±SD   21.91±1.94 22.34±1.89 0.20 0.57 
AoA-ATEE (mm
2
), mean±SD   379.77±67.89 394.73±65.46 0.21 0.57 
AoA-ATEE mismatch (mm
2
), mean±SD  94.14±51.36 83.54±47.40 0.23 0.56 
AoA-ATEE cover index (%), mean±SD 19.72±10.28 17.34±9.97 0.19 0.56 
MDCT characteristics     
AoA-DMaxMDCT (mm), mean±SD   24.74±2.36 25.71±2.34 0.02 0.61 
AoA-DMaxMDCT  mismatch (mm
2
), mean±SD −10.94±66.84 −45.13±73.30 0.01 0.62 
AoA- DMaxMDCT  cover index (%), mean±SD −2.43±14.26 −9.57±14.85 0.01 0.62 
AoA-DMinMDCT (mm), mean±SD   21.08±2.08 21.70±2.08 0.10 0.59 
AoA-DMinMDCT  mismatch (mm
2
), mean±SD 121.64±251.09 105.22±255.03 0.08 0.62 
AoA- DMinMDCT  cover index (%), mean±SD 25.71±10.48 21.94±10.78 0.05 0.63 
AoA-AMDCT (mm
2
), mean±SD   412.21±75.49 440.61±74.55 0.04 0.62 
AoA-AMDCT  mismatch (mm
2
), mean±SD 61.69±49.73 37.67±51.01 0.01 0.65 
AoA- AMDCT  cover index (%), mean±SD 13.00±10.3 7.7±10.39 <0.01 0.66 
TAVI     
Transapical, n (%) 63 (60) 31 (67)   
Transfemoral, n (%) 42 (40) 15 (33) 0.39  
AoA-AMDCT, AoA-A measured by MDCT; AoA-ATEE, AoA-A measured by TEE; AoA-DMaxMDCT, 
maximum AoA-D measured by MDCT; AoA-DMinMDCT, minimum AoA-D measured by MDCT; AoA-DTEE, 
AoA-D measured by TEE; BMI, body mass index; BSA, body surface area; TAVI, transaortic valve 
implantation. 
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The best AoA-AMDCT mismatch cut-off for predicting significant PAR was 61.5 mm
2 by receiver-
operating curve, showing a better performance of MDCT versus TTE and TEE (c value= 0.65 versus 
0.55 and 0.56, respectively) (Figure 4). 
 
Figure 4. Receiver-operating curve (ROC) of predictive model for occurrence of post-procedural 
PAR using AoA-AMDCT mismatch (green curve), AoA-ATTE mismatch (blue curve) and AoA-ATEE 
mismatch (red curve). AoA-AMDCT mismatch showed the best prognostic power for predicting 
significant PAR with a cut-off value of  61.5 mm2 corresponding to a cover index of 13%.  
Table 3 reports the distribution of significant PAR in comparison with the actual size of the 
valves implanted in the study patients, the valve sizes that in principle should have chosen based on 
TEE and MDCT and the number of patients with or without TEE and MDCT valve size matching. 
Theoretically, according to TEE criteria a 23-mm, 26-mm or 29-mm valve were chosen when AoA-
diameter measured by TEE  was between 18 and 21 mm, between 21 and 25 mm and >25 mm, 
respectively. According to MDCT criteria a 23-mm, 26-mm or 29-mm valve were chosen when  AoA-
area measured by MDCT was between 254 and 354 mm2,  between 354 and 469 mm2, and between 
469 and 599 mm2, respectively. TEE and MDCT measurements were in agreement only in 71 out of 
151 (47%) patients (Table 4).  
It is noteworthy that a higher incidence of significant PAR was observed when a smaller 
prosthesis was implanted according to intra-procedural balloon sizing despite both TEE and MDCT 
indicated a larger prosthesis (7 out of 17 versus 9 out of 53 patients, p<0.05). A higher rate of 
significant PAR also occurred when a smaller prosthesis was implanted despite a larger AoA size was 
measured by MDCT as compared to that found with TEE (29 out of 65 patients versus 0 out of 8 
patients, p<0.01). 
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Table 3. Number of patients with significant PAR, comparison between actual size of implanted 
valves and valve sizes that should have been chosen based on TEE and MDCT measurements, 
and number of patients with or without TEE-MDCT valve size matching 
PAR=2 Size of implanted valves Size based on AoA-DTEE Size based on A-AMDCT Patients(n) 
3 23-mm valve 23 23 21 
14 (n = 77 patients) 23 26 34 
0  26 23 5 
7  26 26 17 
0 26-mm valve 23 23 1 
0 (n = 70 patients) 23 26 6 
1  26 23 2 
6  26 26 30 
15  26 29 31 
0 29-mm valve 26 29 2 
0 (n = 4 patients) 29 29 2 
AoA-AMDCT, AoA-A by MDCT; AoA-DTEE, AoA diamter by TEE. 
Table 4. Table 4. Relationship between prosthesis size indication by MDCT vs TEE, size of 
implanted prosthesis and number of patients with significant PAR. 
MDCT vs TEE Prosthesis size 
implanted 
Patients, 
n, (%) 
PAR 
≥2 (n) 
Agreement Concordant 53(35) 9* 
Agreement Smaller 17(11) 7* 
Agreement Larger 1(1) 0 
Oversizing of MDCT vs TE Smaller (according to TEE) 65(43) 29† 
Undersizing of MDCT vs TEE Larger (according to TEE) 2(1) 1† 
Oversizing of MDCT vs TEE Larger (according to MDCT) 8(5) 0 
Undersizing of MDCT vs TEE Smaller(according to MDCT) 5(3) 0 
* P < .05.;† P <.01. 
Discussion 
The main findings of our study are: a) the shape of the AoA is elliptical and not circular; b) there 
is a minimal difference between AoA-minimimum diamater measured by MDCT and both AoA-
diameters evaluated by TTE and TEE,  while a significant  difference was found versus AoA-maximum 
diameter measured by MDCT in comparison with TTE and TEE; c) both TTE and TEE underestimate 
annulus size as compared to MDCT, likely because of the assumption that AoA has a circular shape; d) 
a mismatch of 61.5 mm2 between prosthesis size and AoA-area measured by MDCT is a better 
predictor of PAR as compared to the  mismatch between prosthesis size and TTE and TEE; e) as 
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compared to TEE, AoA assessment by MDCT may lead to implantation of a larger prosthesis in a 
sizable proportion of patients. 
Detaint et al. 15 suggested that the occurrence of significant PAR is related to the lack of 
congruence between the annulus and the device. To appraise the congruence between annulus and 
device size, they used a “cover index” integrating aortic annulus and prosthesis diameters. The 
significant relationship between a low cover index and significant PAR suggests that a certain degree 
of prosthesis over sizing is needed to ensure good apposition of the prosthesis to the aortic annulus. 
Indeed, routine over sizing with prostheses 10–20% larger than the native annulus, as measured by 
TEE, and a trend to a lower valve positioning have been associated with a reduction of PAR rate. 16 A 
possible explanation of AoA size underestimation by echocardiography is the complexity of aortic 
root anatomy. This anatomic area is located between the basal attachment of the aortic valve leaflets 
within the left ventricle and their peripheral attachment at the level of the sinotubular junction 
describing the shape of a crown. 13 The AoA is defined as a virtual ring formed by joining the basal 
attachment points of the leaflets within the left ventricle of this crown-shaped structure. Of note, the 
virtual ring is elliptical in most cases. 13 Measurement of the aortic root by TTE and TEE is limited by 
the 2-dimensional nature of these imaging modalities. Indeed, TTE and TEE do not transect the full 
diameter of the outflow tract. On the contrary, they cut a tangent across the root, providing a 
measurement of the minimum diameter of the elliptical AoA only. This may be the main reason of 
true AoA area underestimation by echocardiography. Although prosthesis over sizing may limit PAR, 
overall this complication still occurs in 65% to 90% of patients, while a moderate-to-severe PAR has 
been reported in up to 20% of patients. 17 Abdel-Wahab et al. 18 recently demonstrated that even 
moderate PAR is associated with a higher incidence of heart failure and in-hospital mortality. On the 
other hand, inappropriate valve over sizing may result in redundancy of leaflet tissue leading to 
altered valve function and reduced durability and even annulus rupture 19. Thus, a more accurate 
annulus sizing with 3-D techniques is desirable. Newer imaging modalities such as MDCT are emerging 
as reliable techniques because they allow precise measurement of the aortic root at any desired 
plane. Tops et al. 9 reported that the annulus has an oval configuration in approximately 50% of 
patients evaluated for TAVI, with a mean difference of 3.01.9 mm between coronal and sagittal 
measurements. Similarly, Delgado et al. 20 described an oval configuration of the annulus with a 
significant difference between the mean coronal and sagittal diameters. Recently, the annulus has 
been evaluated using a 3-chamber reconstruction that replicates the parasternal long-axis view 
obtained with TTE and TEE 21, 22 or using a double oblique transverse imaging orthogonal to the aortic 
root that incorporates the maximal and minimal diameter measurements of the basal ring below the 
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hinge point of the aortic valve cusps 23. It is noteworthy that, regardless of the methods used, the 
absolute difference between MDCT and both TTE and TEE is greater than that between TEE and TTE. 
22 In agreement with previous studies, all our patients showed an elliptical AoA shape with a mean 
difference of 3.77 mm between maximum and minimum diameters. Moreover, the difference 
between the maximum diameter measured with MDCT and those measured with TTE and TEE 
(3.901.98 mm and 3.22.0 mm, respectively) was significantly greater than the <1 mm difference 
found between TTE and TEE diameters. Differently from other studies, we measured the aortic 
annulus area by MDCT. This was done because the true maximum and minimum diameters are not 
located in sagittal and coronal planes as a rule and the aortic annulus orientation may change in each 
patient. Therefore, the area measurement may be more representative of the real annulus size rather 
than the diameter and may give a more appropriate assessment for choosing prostheses of correct 
size. Indeed, a 61.5 mm2 cut-off was identified as a better predictor of significant PAR. Moreover, a 
larger prosthesis would have been chosen according to this cut-off value in 48% of the cases. Of note, 
patients with disagreement between MDCT and TEE measurements and underestimation of aortic 
annulus size with TEE had a higher incidence of significant PAR. These results are in agreement with a 
recent study demonstrating that MDCT modified TAVI strategy in a percentage ranging between 38 
and 42. 22 Imaging assessment similar to MDCT may be obtained without radiation exposure using 3-D 
TEE or cardiac magnetic resonance. Ng et al. 24 demonstrated that 3-D TEE may overcome the 
geometric assumption limitation by allowing direct planimetry of the cross-sectional annular area. 
However, an underestimation of up to 9.6% as compared to MDCT was still found. This is likely due to 
a lower spatial resolution of 3-D TEE volumetric imaging and operator-dependance of this technique. 
Finally, data on cardiac magnetic resonance for the evaluation of patients undergoing TAVI are not 
available yet. 
Limitations of the study 
Several limitations are present in this study. First, as PAR was evaluated by echocardiography at 
the end of the procedure, the shortcomings of assessing eccentric jets by echocardiography have to 
be kept in mind. 25 Second, the incongruence between prosthesis and aortic annulus area was 
considered as the underlying cause of aortic regurgitation. However, several other mechanisms may 
be involved such as valvular damage during implantation, too low implantation of the valve and valve 
malapposition due to severe calcifications. However, all these conditions were ruled out in the 
unbiased analysis of the data. Third, patients with inadequate echocardiography window or 
impossibility to perform MDCT with ECG triggering were excluded from the present study.  
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Conclusions 
This study shows that the lack of congruence between prosthesis and annulus size is associated 
with PAR. MDCT is a better tool for detecting the mismatch between prosthesis area and aortic 
annulus area and for predicting PAR as compared to TTE and TEE. An MDCT-based approach may be a 
reliable method to select the appropriate prosthesis size for TAVI. In this regard, specific MDCT-based 
sizing recommendations should be developed.  
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Summary and Conclusion  
Summary 
The general introduction of the thesis outlines the characteristics and indications of TAVI, and 
the current and future role of cardiac imaging modalities (2D/3D TTE/TEE, MDCT, MRI) in the 
diagnostic process and for decision-making in this setting. 
Chapter 1 illustrates the feasibility and accuracy of 3D TTE compared to 2D TTE and MDCT for 
the measurement of aortic annulus dimensions in the preoperatory evaluation of patients candidates 
to TAVI. 3D TTE evaluation was feasible in the majority of the patients with low intra and inter 
observer variability.  3D TTE and MDCT measurements did not differ significantly, with excellent 
agreement in the selection of cases with too small or too large annulus (recognized exclusion criteria 
for TAVI) while, as expected due to the oval shape of the aortic annulus, the 2D TTE annulus area, 
geometrically derived from 2D TTE diameter, was considerably lower in comparison both with 3DTTE 
and MDCT planimetric surface area. A good agreement in the choice of prosthetic size in cases 
scheduled for the procedure was found between the 3D TTE and MDCT. Subsequently, even though 
it’s known that MDCT provides precise information about the annulus anatomy and remains the gold 
standard for the pre-operative assessment of TAVI candidates, 3D TTE may play a role in those 
patients that can’t be studied by MDCT for several reasons such as impaired renal function, severe 
breathlessness, and arrhythmias. 3D TTE does not require breath-old and contrast infusion, may be 
obtained at the bedside, in more critical cases, and also in the presence of arrhythmias. 
Chapter 2 shows that CMR, due to its multiplanar reformatting capabilities, allows accurate 
short-axis visualization of the aortic annulus and precise measurement of the virtual ring 
corresponding to the site of prosthesis deployment with high reproducibility and accuracy as 
compared to MDCT. Moreover, it can estimate the coronary ostia height and aortic valve leaflet 
dimensions that is a key step for patient selection and procedural planning in order to prevent 
coronary obstruction during TAVI. 
In Chapter 3 a large series of aortic patients was studied to evaluate the capability of 3D TEE to 
estimate preoperatively the distance between the aortic annulus and the left main ostium (AoA-LM), 
its accuracy in comparison with MDCT-derived measurements, the ability of the 3DTEE-derived 
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measurements in predicting the stent landing zone as defined by the overlap of the prosthesis with 
mitral leaflet.  
The results demonstrated that 3D TEE may estimates the AoA-LM distance as an alternative 
technique to MDCT. Moreover, 3D TEE allows an immediate evaluation of the distance between the 
mitral leaflet and aortic prosthesis after the implantation. This measurement was feasible in most of 
the cases (90%) and also accurate. In fact the 3D TEE computed prosthesis was similar to the 
prosthetic nominal value. Pre and post 3D TEE data concerning the valve and prosthesis morphology 
and simultaneous real time evaluation of the aortic root including the LM coronary ostium give new 
insights regarding TAVI and its complications.  
Chapter 4 suggests that intraoperative 2D and 3D TEE may allow the identification of predictors 
of significant PAR following successful TAVI. In particular, incomplete device expansion due to aortic 
valve calcifications is believed to be one of the contributing factors to PAR post-TAVI. In fact, heavily 
calcified native aortic valves may not allow a perfect apposition of the device along the annulus 
circumference. Our data show that the calcifications of the commissure between the right coronary 
and non-coronary cusp is related to significant post-procedural PAR. Moreover, the measurement of 
an “area cover index”, defined as the percentage difference between planimetered aortic annulus 
area and the nominal prosthesis area, should be considered during patient selection for TAVI. As a 
low “area cover index” predicts the development of significant post-procedural PAR, this index could 
be utilized as an additional parameter when choosing the prosthetic size in all those patients with 
borderline 2D TEE annulus size. Probably a certain degree of prosthetic oversizing is needed in order 
to minimize the development of significant PAR after the procedure. 
Chapter 5 shows that, in accordance with previous results, the lack of congruence between 
prosthesis and annulus size is associated with significant PAR. MDCT is a valuable modality for 
detecting the mismatch between prosthesis area and aortic annulus area and for predicting PAR. In 
details, a mismatch of 61.5 mm2 between prosthesis size and aortic annulus area measured by MDCT 
is a predictor of PAR. 
Conclusions 
TAVI is an invasive technique whose success depends on multidisciplinary team approach, 
where imaging fulfils a definite part. Initial experience with TAVI was based on 2D echocardiography 
measurements. There is now evidence that a 2D approach to the anatomy of the aortic valve 
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apparatus is inadequate. Advanced cardiac imaging modalities, 3D echocardiography, MDCT and MRI, 
besides standard 2D echocardiography and angiography, play a crucial role in the diagnostic process 
and management of patients, allowing proper selection and planning, optimizing the procedure and 
increasing TAVI success. Echocardiography is the cornerstone of pre-procedure evaluation, 
complemented by MDCT. Both 3D TTE/TEE and MDCT have a higher predictive value for PAR than 2D 
echo measurements and have been shown to change valve sizing strategy compared with 2D echo. 
During TAVI, 2D, and particularly 3D, TEE can be used for guidance and, allowing the visualization of 
the left main ostium and the measurements of its distance from the annulus, increases the procedure 
safety. 
In the future, as patients undergoing TAVI might be younger, CMR might gain significance by 
the absence of radiation issues. 
